US20210236065A1 - System and method for disease risk assessment and treatment - Google Patents
System and method for disease risk assessment and treatment Download PDFInfo
- Publication number
- US20210236065A1 US20210236065A1 US17/100,833 US202017100833A US2021236065A1 US 20210236065 A1 US20210236065 A1 US 20210236065A1 US 202017100833 A US202017100833 A US 202017100833A US 2021236065 A1 US2021236065 A1 US 2021236065A1
- Authority
- US
- United States
- Prior art keywords
- sepsis
- risk
- sensor array
- analytes
- risk score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 26
- 238000012502 risk assessment Methods 0.000 title claims description 5
- 201000010099 disease Diseases 0.000 title description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 18
- 238000011282 treatment Methods 0.000 title description 15
- 206010040047 Sepsis Diseases 0.000 claims abstract description 117
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 90
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 68
- 239000008103 glucose Substances 0.000 claims abstract description 68
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000001301 oxygen Substances 0.000 claims abstract description 60
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 60
- 238000001514 detection method Methods 0.000 claims abstract description 10
- 210000001519 tissue Anatomy 0.000 claims description 43
- 239000012491 analyte Substances 0.000 claims description 39
- 238000005259 measurement Methods 0.000 claims description 36
- 230000008859 change Effects 0.000 claims description 35
- 206010033675 panniculitis Diseases 0.000 claims description 15
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 15
- 230000007175 bidirectional communication Effects 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 description 52
- 230000006854 communication Effects 0.000 description 26
- 238000004891 communication Methods 0.000 description 26
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 230000001965 increasing effect Effects 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 19
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 19
- 238000012545 processing Methods 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 14
- 238000005070 sampling Methods 0.000 description 14
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 11
- 230000036571 hydration Effects 0.000 description 11
- 238000006703 hydration reaction Methods 0.000 description 11
- 238000007726 management method Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 208000017667 Chronic Disease Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000010801 machine learning Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000035778 pathophysiological process Effects 0.000 description 5
- 230000000737 periodic effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010024774 Localised infection Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 230000006682 Warburg effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000011511 automated evaluation Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 238000000157 electrochemical-induced impedance spectroscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000003166 hypermetabolic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000037000 normothermia Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/076—Permanent implantations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6861—Capsules, e.g. for swallowing or implanting
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0204—Operational features of power management
- A61B2560/0214—Operational features of power management of power generation or supply
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/06—Accessories for medical measuring apparatus
- A61B2560/063—Devices specially adapted for delivering implantable medical measuring apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/06—Arrangements of multiple sensors of different types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
Definitions
- the invention generally relates to systems and methods for real time metabolic monitoring to enable diagnosis and monitoring of disease progression including risk assessment, diagnosis, treatment and monitoring of sepsis. More specifically, the invention relates to the use of sensors and related electronics in conjunction with algorithms and software for the early identification and warning before the onset of sepsis.
- Sepsis is a medical condition that is the result of a severe inflammatory response to a circulation infection.
- Current estimates suggest that approximately one-million Americans will develop sepsis on an annual basis and between 30 and 50 percent of those patients will succumb due to sepsis related complications such as multi-organ failure.
- the economic burden of sepsis is significant with recent estimates suggesting yearly in patient costs well in excess of $22 billion.
- the economic burden of sepsis is expected to increase dramatically in the coming years given the increasing prevalence and incidence of sepsis due in large part to both increased life expectancy and an increase in antibiotic resistant bacteria.
- the costs associated with treating sepsis are significant in part due to the intensive care unit (ICU) as being the primary venue for highly invasive early goal directed treatment (EGDT) strategies that use the output of centrally placed catheters capable of measuring arterial pressure in comparison to a goal to modify or modulate the use of intravenous fluids, oxygen, drugs and blood transfusions in what can be a futile fight for survival.
- ICU intensive care unit
- EGDT early goal directed treatment
- a randomized control trial (RCT) published in 2001 showed via a single-site, EGDT administration of a hemodynamic driven protocol for six hours following diagnosis and triage resulted in a reduction of in-hospital mortality from 46.5% to 30.5% and evolved into the standard of care and has been included in the six-hour sepsis bundle protocol used by many hospitals.
- a larger RCT named Protocol Care for Early Septic Shock (ProCESS) sought to replicate the previously discussed results within a larger population enrolled across a large number of diverse academic hospital emergency departments.
- the ProCESS trial demonstrated no improvement in 60-day survival rates between the EGDT and normal care cohort.
- the overall mortality rate within all cohorts of the ProCESS clinical trial group was approximately 21% ( ⁇ 30% at 90 days), which was substantially lower than in hospital mortality rate documented in the previous study thereby suggesting improvements in nominal sepsis related care.
- the claimed invention seeks to address timely and cost effective methods and systems to diagnose sepsis.
- multiple analytes and physical parameters are monitored.
- diagnosis is based on monitoring multiple analytes without physical parameters. While embodiments and examples may be related to particular analytes and physical parameters, the scope of the disclosure and claims should not be construed to be limited to the specifically addressed analytes and parameters. Rather it should be recognized that additional or other analytes and physical parameters can be monitored to assist in the detection and diagnosis of sepsis.
- a system to enable risk assessment of the onset of sepsis includes a sensor array for insertion within subcutaneous tissue for continuous monitoring of at least two analytes that are indicators of the onset of sepsis. Further included within the system is an electronics module that includes a power supply, a processor, memory, and a bi-directional communications module. In one embodiment the electronics module is configured to couple with the sensor array while a power supply powers the sensor array and a processor is in communication with the sensor array. The processor calculates a risk index for the onset of sepsis based on characteristics of the at least two analytes being continuously monitored. The risk index being transmitted to and stored on a computer readable electronic health record.
- an apparatus for early detection of sepsis in a host includes a first sensor to directly measure a glucose level, a second sensor to directly measure a lactate level and a third sensor to directly measure a tissue oxygen level.
- the first sensor, the second sensor, and the third sensor all being inserted at a single point of entry in a subcutaneous space of the host such that a predetermined correlation between the glucose level, lactate level, and tissue oxygen level signals conditions related to sepsis.
- a method for the early detection of sepsis in a host includes an operation that inserts via a single point of entry a sensor assembly having a first sensor, a second sensor and a third sensor into subcutaneous tissue of the host. The method continues with an operation to measure a glucose level using the first sensor. An additional operation measures a lactate level using the second sensor, while still an additional operation measures tissue oxygen level using the third sensor. A subsequent operation determines a risk index for sepsis based on predetermined correlations between the glucose level, the lactate level and the tissue oxygen level.
- a method for the early detection of cancer includes a first operation of inserting a sensor assembly having a first sensor and a second sensor via a single point of entry into subcutaneous tissue. Other operations measure a first analyte level with the first sensor and a second analyte level with the second sensor. The second analyte being different than the first analyte.
- the method further determines a risk index for cancer based on predetermined correlations between the levels of the first analyte and second analyte. Wherein the first analyte and second analyte are selected from a group consisting of glucose, lactate, oxygen or a ketone.
- Another embodiment discloses a method to monitor for a medical condition that includes an operation that identifies at least two different biological markers relevant to the pathophysiological process of the medical condition.
- a later operation enables at least two sensors to measure the at least two identified biological markers.
- a later operation configures the sensors onto a sensor array that is applied at a single site and another operation monitors the biological markers for pathophysiological conditions indicative of development of the medical condition.
- FIG. 1A is an exemplary block diagram showing components within a system to determine a risk score of developing sepsis, in accordance with embodiments of the invention.
- FIGS. 1B-1 and 1B-2 are exemplary isometric views of sensor array 101 , in accordance with embodiments of the invention.
- FIG. 2A is an exemplary flowchart illustrating operations performed by various components of the system to determine a risk score for sepsis, in accordance with embodiments of the invention.
- FIG. 2B is an alternative embodiment of FIG. 2A , in accordance with embodiments of the invention.
- FIG. 3A-1 is an exemplary hybrid flowchart and block diagram illustrating operations and elements used to perform an operation that evaluates data to determine a risk score, in accordance with embodiments of the invention.
- FIG. 3A-2 is an exemplary hybrid flowchart and block diagram further including the application of conditional logic or conditional weights, in accordance with embodiments of the invention.
- FIG. 3B is a hybrid flowchart and block diagram illustrating exemplary operations within the metrics processing module, in accordance with embodiments of the invention.
- FIG. 4A is an exemplary chart illustrating how temperature risk metrics are converted to normalized temperature risk values, in accordance with embodiments of the invention.
- FIG. 4B is an exemplary chart illustrating conversion of lactate sensor readings to normalized lactate risk values, in accordance with embodiments of the invention.
- FIGS. 4C and 4D are exemplary charts illustrating how glucose risk values can change, in accordance with embodiments of the invention.
- FIG. 4E is an exemplary chart of risk values associated with a secondary input, specifically, a rate of change of lactate, in accordance with embodiments of the invention.
- FIG. 5 is an exemplary flowchart illustrating integration of the system within a therapy management system to enable a feedback mode in accordance with embodiments of the invention.
- FIG. 6 includes a table of exemplary triage mode relative weight coefficients for patients with and without diabetes, in accordance with embodiments of the invention.
- FIG. 7 includes a table of exemplary relative weighting coefficients for particular metrics, in accordance with embodiments of the invention.
- Simultaneous continuous or periodic measurement of physical parameters and chemical entities as a means of measuring disease progression or inflection that requires timely clinical intervention can be extended to a multitude of disease states and may include multiple measurement modalities.
- the design of such medical monitoring systems requires an understanding of the pathophysiological processes associated with a particular illness or disease. From this basic understanding, a number of small molecules, biological markers of disease, and physiological measures with high diagnostic and prognostic value for a particular disease and/or condition can be identified.
- Sensors that rely on physical, electrochemical, and optical transducers can be functionalized to directly or indirectly measure the small molecules, biological markers, and physiological measures associated with a specific disease.
- Advanced manufacturing techniques can then be used to integrate the sensors in question into a multi-analyte or multi-parameter that can be deployed invasively or noninvasively within a target population.
- Software algorithms that combine an understanding of disease, artificial intelligence, and machine learning can be embedded in the instrumentation or systems that power and acquires data from a disease specific multi-parameter sensor to assess the cellular and/or systemic progression of condition or disease.
- Configurable alerts and alarms associated with the medical monitoring system can be communicated through wired and wireless methods to enable timely therapeutic intervention in order to derive the benefits of proactive disease or illness management.
- the risk score for developing sepsis is determined using risk metrics based on data obtained from (i) sensors placed implanted within or associated with a subject and/or (ii) other external input available on the subject (such as electronic medical records, test data from hospital/clinic measurements where the subject is being evaluated, or has been evaluated previously, for a medical condition).
- Risk metrics based on sensor data can be based on continuous and substantially real-time monitoring of analytes and physiological parameters relevant to sepsis.
- the risk metrics includes, but is not limited to analytes such as, glucose, tissue oxygen and lactate.
- Detectable changes in those risk metrics can be indicative of a localized infection progressing towards sepsis.
- the pathophysiological processes of a localized infection developing into sepsis and the relationship between glucose, lactate and tissue oxygen is described below.
- a localized infection initially begins progressing toward sepsis there can be a rapid increase in insulin resistance that results in a measurable increase in glucose.
- Undetected and untreated the infection can continue to progress towards sepsis where the measureable increase in glucose eventually begins coinciding with a measureable decrease in tissue oxygen.
- Further progression toward sepsis results in decreased tissue oxygen coinciding with an increase in lactate levels and highly elevated lactate level, in conjunction with other factors, can be indicative of a septic infection.
- analysis of continuous real time measurements of glucose, lactate and tissue oxygen in light of the pathophysiological process described above enables determination of a risk score of developing sepsis.
- the risk score is determined based on a sum of normalized primary inputs, where primary inputs are sensor measured concentrations of analytes such as, but not limited to, glucose, tissue oxygen and lactate.
- primary inputs are sensor measured concentrations of analytes such as, but not limited to, glucose, tissue oxygen and lactate.
- secondary inputs are risk metrics that are calculated based on primary inputs. Examples of secondary inputs include, but are not limited to rates of change of glucose, tissue oxygen and lactate.
- the risk score additionally incorporates looking at measured inputs over time differently. For example, rather than using the same time window for all evaluations, each analyte or metric is examined at a preferred frequency.
- Relative weighting factors can also be applied to either or both primary and secondary inputs to emphasize or deemphasize particular risk metrics when determining a risk score.
- Sources for relative weighting are found in personal health records such in measured or calculated metrics or be derived from personal health records.
- An example of relative weighting derived from measured metrics includes, but is not limited to decreasing the influence of high lactate concentrations when coincident with nominal lactate clearance rates.
- An example of relative weighting derived from personal health records is increasing weighting for all metrics when a subject is immunocompromised.
- the system is configurable for use in a variety of environments including, but not limited to triage, patient monitoring and remote monitoring, where each mode may be further supplemented with a feedback/treatment mode.
- a triage environment the system determines a risk score that can help determine if a patient may have developed sepsis.
- the risk score and changes to the risk score over time enables both automated evaluation if a patient may be trending toward developing sepsis and automated evaluation of efficacy of therapy for patients known to be septic.
- the risk score enables monitoring of patients for early warning signs indicative of the onset of sepsis.
- the system is applied to a patient entering a medical facility such as, but not limited to an emergency room, an urgent care clinic or a mobile medical emergency environment such as an ambulance or helicopter.
- a medical facility such as, but not limited to an emergency room, an urgent care clinic or a mobile medical emergency environment such as an ambulance or helicopter.
- Other alternative triage environments include locations with elevated numbers of high risk individuals such as elder care facilities, nursing homes and hospice facilities.
- the system is intended to rapidly determine a risk score for sepsis based on risk metrics that are indicative of an existing sepsis condition. This enables initiation of goal directed therapy for the treatment of sepsis within a minimal amount of time.
- the system is capable of transitioning from a diagnostic tool to a monitoring device capable of providing data to assist in evaluating the efficacy of ongoing therapy. Assuming a triage patient is deemed to not be septic, the system can transition to a patient monitoring mode where the objective is to output a risk score that provides notification that a patient is trending toward conditions indicative of sepsis.
- the system enables monitoring of septic patients, continued analysis of data from triage patients and further includes monitoring of postoperative patients.
- the patient monitoring environment is an ambulatory patient within a medical care facility such as a hospital or an outpatient clinic.
- the system can provide real time continuous monitoring of analytes that are indicative of the efficacy of ongoing therapy.
- the real time continuous data can enable more frequent and responsive changes in goal directed therapy. For example, rather than having to wait for discrete lactate samples to be returned from a laboratory, with real time continuous monitoring physicians can easily see if lactate levels are increasing or decreasing and additionally the rate at which lactate levels are changing. With rate of change data, physicians can change and modify treatment protocols and see the results of previous changes more rapidly than with discrete samples that may take hours to return from the laboratory.
- the system continues to generate a risk score for developing sepsis with the objective of providing notification that a patient may be trending toward conditions indicative of sepsis.
- various care protocols may require increased monitoring of the patient.
- updated care protocols may proscribe early intervention and application of goal directed therapy to halt further trending towards sepsis that minimize the likelihood of the patient continuing to trend toward sepsis.
- the system can further be transitioned from a medical care facility to a mobile monitor capable of operating as a home monitor or any other location outside of a medical care facility.
- a mobile monitor capable of operating as a home monitor or any other location outside of a medical care facility.
- Use of the system as a mobile monitor may be desirable for patients being discharged from a medical facility that may be considered high risk to develop sepsis such as an elderly postoperative patient.
- the remote monitoring capability of the system can be expanded to generally high risk individuals such as those with compromised immune systems, and those living in elder care, nursing homes or hospice facilities.
- the goal for remote monitoring is to provide early notification that a patient is trending toward a condition indicative of sepsis. In many of these embodiments it may not be desirable to monitor lactate while scrupulously monitoring rates of change of glucose and oxygen.
- the notification is provided to the patient while in other embodiments the notification is provided to an attending physician.
- notification is provided to both the patient and at least one medical or care professionals such as, but not limited to an attending physician, nurse, resident healthcare provider, or a centralized care facility that can contact EMS. Similar to patient monitoring use of the system as a remote monitor can result in a patient seeking more timely application of goal directed therapy that containing an infection to a localized system and minimizes the likelihood of the infection becoming systemic.
- Feedback mode is intended to monitor the effects of any treatment protocol and provide real-time, actionable information to external control algorithms whose aim is to optimize the management of therapy delivery to subjects with sepsis or a high risk of developing sepsis. In many embodiments, this is accomplished by modifying therapy based on system outputs achieving targets and/or set points for specific risk metrics based on a specific clinical protocol.
- FIG. 1A is an exemplary block diagram showing components within a system 100 to determine a risk score of developing sepsis, in accordance with embodiments of the invention.
- the system 100 includes a sensor array 101 that includes analytes sensors 101 a and physical sensors 101 b powered by an electronics module 102 that further enables bi-directional communication with a plurality of remote devices, such as, but not limited to an external monitor 104 , cloud computing systems 106 and mobile devices 128 .
- the remote devices enable different aspects of functionality of the system 100 , such as, but not limited to entry of patient specific data, display of historical and trending data acquired by the system 100 , and machine learning.
- FIG. 1A enable the system 100 to be used across a variety of environments such as triage, patient monitoring and remote monitoring.
- embodiments tailored for a specific environment may not include all of the components shown in FIG. 1A .
- use of the system 100 as a remote monitor in a home may not utilize an external monitor 104 .
- the system 100 may not include a mobile device 128 .
- the inclusion of all of the components within FIG. 1A is intended to illustrate the flexibility and adaptability of the system 100 to be used in different environments.
- an element of the system 100 that is required for all embodiments is the sensor array 101 .
- FIGS. 1B-1 and 1B-2 are exemplary isometric views of sensor array 101 , in accordance with embodiments of the invention.
- the sensor array 101 includes a plurality of analyte sensors such as, but not limited to sensors configured to continuously measure glucose, lactate and oxygen or combinations thereof.
- the respective analyte sensors are formed either first sensor assembly 1001 or second sensor assembly 1002 that are placed or coupled with a sensor carrier 1003 .
- Sensor carrier 1003 includes area 1005 that is configurable to receive physical sensors, such as, but not limited to thermometers, accelerometers and the like.
- Insertion hollow 1004 running through the sensor carrier 1003 enables insertion of the sensor array 101 via a single point of entry using an insertion sharp such as, but not limited to a needle.
- the insertion hollow 1004 can optionally be utilized to place additional physical sensors within the subject such as, but not limited to a discrete tissue fluid monitoring sensor, e.g. a subcutaneous tissue impedance measurement system.
- the sensor array 101 includes a combination of any two of glucose, lactate and oxygen sensors. In other embodiments, the sensor array includes 101 includes at least one each of glucose, lactate, and oxygen sensors.
- the respective sensors for glucose, lactate and oxygen are electrochemical sensors that include multiple electrodes or transducers that are dispersed along and/or among first sensor assembly 1001 and second sensor assembly 1002 .
- the glucose sensor can include a single or multiple glucose measuring electrodes found on either first or second sensor assemblies 1001 and 1002 . Implementation of multiple electrodes for a particular analyte can enable redundancy or may be necessary to generate sufficient measurable electrical current.
- the sensor array 101 further includes additional sensors or abilities to measure physical characteristics such as, but not limited to movement (via accelerometers), temperature, tissue impedance (such as tissue hydration levels related to development of edema), skin impedance and sensor hydration levels.
- the specific physical sensors discussed should not be construed as limiting.
- Other and additional physical characteristics from physical sensors associated with the sensor array 101 can be used as risk metric inputs to the risk score.
- Monitoring hydration levels of at least one some, or all of the sensors within the sensor array 101 enables detection of whether the sensor array 101 is properly implanted within desirable tissue. Additionally, monitoring the sensor elements for proper hydration can be used as a trigger to enable at least one of calculation of a risk score, data recording, and/or data transmission.
- Electrochemical impedance spectroscopy applied across any electrode pair within the sensor array 101 can be used to measure or infer tissue impedance to determine tissue hydrations levels, or a fluid status within subcutaneous tissue of a subject being monitored.
- fluid status of a subject is a risk metric contributing to the risk score of developing sepsis because fluid status provides context and a normalizing factor for other measurements, such as, and not limited to real time glucose, oxygen and lactate. Additionally, fluid status enables inference of capillary dysfunction which is an indicator of systemic inflammatory response syndrome (SIRS) or an ongoing progression of sepsis.
- SIRS systemic inflammatory response syndrome
- tissue hydration levels enable adjustment or modifications to a risk score because goal directed fluid management can lose its effectiveness if the sign of fluid buildup (increasing tissue hydration levels or increasing rate of change of tissue hydration levels) are emerging.
- tissue hydration levels enable additional insight regarding perfusion of analytes within different types of tissues. For example, in various embodiments tissue hydration levels for a sensor array 101 placed in muscle provides additional or less information than a sensor array 101 that is placed in adipose tissue.
- two of the three analyte sensor values are combined with data from any to all of the physical characteristic sensors to determine a risk score of developing sepsis.
- all three of the analyte sensor values are used in conjunction with the data from any one to all of the physical characteristic sensors to determine a risk score of developing sepsis.
- the rationale for enabling risk score calculations based on less than all three analytes is to enable tailoring of the sensor array to a particular environment. For example, it may not be necessary to monitor glucose for a septic patient being monitored to determine efficacy of the therapy.
- monitoring of glucose maybe optional because elevated glucose, as a metric within the system, is used to determine if an infection is progressing toward sepsis.
- the system may be highly tuned to monitor for elevations in glucose accompanied by decreases in tissue oxygen levels and optionally forgo any measurement of lactate.
- the analyte sensors are intended to be placed in subcutaneous tissue where the plurality of working electrodes within the sensor array 101 produce a corresponding plurality of signals. Placement within subcutaneous tissue enables a unique perspective for an oxygen sensor that is substantially different than common SpO2 oxygen measurements. Specifically, with embodiments of the analyte sensors 101 a, oxygen within tissue is being measured rather than a measurement of SpO2 which is an estimation of arterial oxygen. When determining a risk score of developing sepsis it is advantageous to measure oxygen within tissue rather than estimated arterial oxygen because oxygen within tissue is a direct measurement of oxygen perfusion which is an early indicator of organ failure.
- Supplementing the tissue oxygen signal are signals from the lactate and glucose sensors where each respective signal is proportional to an amount of analyte present in the subcutaneous tissue.
- a two-electrode system is employed where each of the working electrodes electrochemically measure a particular analyte relative to a counter electrode.
- a three-electrode system is employed where each of the working electrodes electrochemically measure a particular analyte relative to a counter and reference electrode.
- each working electrode has a corresponding counter electrode while in other embodiments multiple working electrodes share a counter electrode. In still other embodiments, two working electrodes share a counter electrode while the third working electrode has a dedicated discrete counter electrode.
- the various embodiments of working electrodes and counter electrodes can be distributed among separate and discrete substrates. Typically, working electrodes and counter/reference electrodes are formed on a single substrate. However, an electrode design intended for use in the invention allows the complete physical separation of any of the working electrodes and any of the counter/reference electrodes. For example, as is shown in FIGS. 1B-1 and 1B-2 working electrodes for analyte sensors can be formed on first sensor assembly 1001 while counter electrode are formed on second sensor assembly 1002 .
- the sensor array 101 having the plurality of working electrodes is inserted into the subcutaneous tissue via a single point of insertion.
- the use of a single insertion point minimizes both patient discomfort associated with insertion and insertion complexity.
- the embodiments described above should not be construed as limiting.
- the sensor array should not be perceived as limited to subcutaneous placement for measurement of glucose, tissue oxygen and lactate.
- Other embodiments, for use in diagnosing or determining risk score for other conditions or diseases can employ various sensors to measure other combinations of analytes in different locations within the subject.
- the system 100 additionally includes an electronics module 102 that provides power for the sensor array 101 and enables bidirectional communication with other system components such as, but not limited to the external monitor 104 , cloud computing systems 106 or mobile devices 128 . Enabling the electronics module 102 to perform such tasks are electronic module components such as, but not limited to a communication module 108 , a processor 110 , memory 112 , and a power supply 114 enclosed within an electronics module case.
- the electronics module 102 includes additional components, however, the specific components found in FIG. 1A warrant discussion regarding operation of the system 100 .
- the power supply 114 provides power to the electronics module 102 and also to the sensor array 101 .
- Batteries, rechargeable or disposable, can be used for the power supply 114 .
- inductive charging for embodiments using rechargeable batteries.
- Other embodiments use alternatives to batteries such as, but not limited to capacitors, supercapacitors, solar cells, fuel cells and the like.
- the specific examples provided for the power supply 114 should not be construed as limiting. Rather, the examples provided should be viewed as examples of portable power supplies capable of supplying the electronics module 102 and the sensor array 101 with power for the expected life of the system 100 .
- the processor 110 is custom circuit such as but not limited to an application-specific integrated circuit (ASIC) or field programmable gate array (FPGA).
- the processor 110 is a more generic system on chip (SoC) or system in package (SiP).
- SoC system on chip
- SiP system in package
- communication module 108 and memory 112 can be integrated within the SoC or SiP.
- the processor is in communication with the sensor array 101 receiving raw signal data from the plurality of working electrodes and other sensors.
- the processor 110 performs minimal manipulation of the raw data from the working electrodes. Examples of minimal manipulation include, but are not limited to filtering noise and compression.
- the data from the working electrodes is transmitted to a multitude of external devices via the communication module 108 where processing is completed to produce a risk score for sepsis.
- the processor 110 executes stored instructions to process the sensor data before transmitting processed data that may include a risk score for sepsis to any external devices via the communications module 108 .
- the communications module 108 is based on personal area network technology commonly referred to as Bluetooth low energy (BLE) or Bluetooth Smart. In other embodiments, a customized or semi-custom communication standard is utilized. However, one common trait for any communication module 108 is the ability to securely send and receive data between at least a third party device and the electronics communication module 102 . The ability to securely transmit either raw or processed data using the communications module 102 enables flexibility that allows the system 100 to be adaptable from a mobile monitor to being an integral component within a hospital ward.
- BLE Bluetooth low energy
- a customized or semi-custom communication standard is utilized.
- one common trait for any communication module 108 is the ability to securely send and receive data between at least a third party device and the electronics communication module 102 .
- the ability to securely transmit either raw or processed data using the communications module 102 enables flexibility that allows the system 100 to be adaptable from a mobile monitor to being an integral component within a hospital ward.
- data from the sensor array 101 is sent via the communications module 108 to a cloud computing system 106 , also commonly referred to as “the cloud”.
- data from the sensor array 101 is transmitted via the communications module 108 to an external monitor 104 .
- Clinical settings such as a hospital ward where multiple monitors display a plurality of condition being monitored for a patient could be ideal settings for embodiments where the electronics module 102 transmits to an external monitor 104 or the cloud 106 .
- the appropriate infrastructure data from the sensor array 101 can be transmitted in real-time to an electronic medical record stored in the cloud 106 .
- data can be transmitted from the external monitor 104 to the cloud 106 where it is stored as part of an electronic medical record.
- the electronics module 102 transmits data from the sensor array 101 to a mobile device 128 such as, but not limited to a smartphone, a smartwatch, a portable fitness monitor, a tablet, a notebook computer, an ultrabook computer, or an aftermarket or integrated infotainment center for a vehicle.
- a mobile device 128 such as, but not limited to a smartphone, a smartwatch, a portable fitness monitor, a tablet, a notebook computer, an ultrabook computer, or an aftermarket or integrated infotainment center for a vehicle.
- the examples of a mobile device 128 are not intended to be construed as limiting. Rather, the examples are intended to provide guidance regarding the types of devices that can receive and/or transmit data to the electronics module 102 . Accordingly, devices that can be viewed as similar to those listed should be considered contemplated by the current disclosure.
- the mobile device 128 can send data to the cloud 106 where the data can be archived, shared with other devices, be further processed or become data to enable machine learning.
- Utilizing the data to enable machine learning further enables data-driven improvements such as development of algorithms that are patient specific or algorithms that are applied universally across all patients. For example, depending on how much information is provided with the data provided for machine learning, patient specific algorithms can include, but are not limited to factors such as age, race, weight, and pre-existing conditions. Similarly, regardless of patient specific information, all data processed via machine learning can be utilized to improve algorithms with the goal being improved outcomes for all patients.
- memory 112 can be used to store data from the sensor array 101 on the electronics module 102 . Using the memory 112 to store data from the sensor array 101 can ensure sensor data is not lost if there are connectivity interruptions between the electronics module 102 and the external monitor 104 , the cloud 106 , or a mobile device 128 .
- the memory 112 can further be used to store program instructions for the processor, or to store values for variables used by the processor 110 to output a risk factor for sepsis.
- the electronics module 102 is removably coupled with the sensor array 101 .
- the electronics module 102 is capable of being reused after the sensor array 101 is deemed consumed or depleted.
- a permanent coupling is achieved after an initial coupling between the electronic module 102 and the sensor array 101 .
- the electronics module 102 is considered disposable and is intended to be discarded after the sensor array 101 is deemed consumed.
- select portions of the electronics module such as, but not limited to the power supply 114 and communications module 108 are recyclable.
- initially coupling the electronics module 102 to the sensor array 101 provides power to the electrodes and initiates the program instructions stored in either the processor 110 or the memory 112 .
- the electronics module includes a feedback device 113 .
- the feedback device 113 provides feedback regarding the status of the combined electronics module 102 and sensor array 101 .
- the feedback device 113 is a single or a plurality of multi colored LED that blinks a first color and/or first pattern when the system is functioning with design parameters and a second color and/or second pattern if there is an error within the system.
- the LED is a single color that uses different frequency of blinks to convey status of the system.
- the feedback module includes a vibration device similar those used in mobile phones to convey status of the system.
- a piezo or other audible sound emitting device is used as the feedback device 113 .
- the external monitor 104 may include some components not found in the electronics module 102 , such as a graphic user interface (GUI) 122 and a display 124 .
- Other components of the external monitor 104 such as a communication module 116 , a processor 118 , a memory and a power supply 126 may seem duplicative of components in the electronics module 102 , but may have different or improved capabilities or functionality.
- the power supply 114 of the electronics module 102 may be a battery
- the power supply 126 for the external monitor 104 may include an AC power supply that is supplemented with a rechargeable battery to enable the external monitor 104 to operate seamlessly between being plugged into a wall socket and being moved throughout a hospital until it can be eventually be plugged back into a wall socket.
- the GUI 122 further includes human interface devices that enable interaction with the GUI 122 such as but not limited to virtual or physical keyboards, touchscreens, joysticks, control pads and the like. Accordingly, use of the GUI 122 in conjunction with the display 124 enables user input to the system 100 and further allows selection or customization of what is shown on the display 124 .
- the GUI 122 in conjunction with the communication module 116 and the communication module 108 further enables settings on the electronics module 102 to be manipulated or adjusted to optimize output from the system 100 .
- the GUI 122 enables user input to the processor 118 or the memory 120 to enable input and adjust settings that are applied to data from the sensor array 101 to determine a risk factor for sepsis.
- the system further optionally includes a mobile device 128 having a user interface, such as, but not limited to a smartphone, a mobile phone, a smartwatch, a laptop, an ultrabook, a tablet computing device, a pager, and the like.
- the mobile device 128 is configured to receive data from the electronics module 102 via at least one of the cloud 106 , the external monitor 104 , or the electronics module 102 itself.
- the mobile device 128 is in bidirectional communication with the electronics module 102 which enables input via the user interface of the mobile device 128 to be transmitted to the electronic module 102 . This enables a user of the mobile device 128 to manipulate, configure, or program settings on the electronics module 102 .
- bidirectional communications enables processing of data from the sensor array 101 on the mobile device 128 .
- the mobile device 128 includes a display
- real time data and trends derived from the data is shown on the mobile device 128 .
- the mobile device 128 can be used to update users of the mobile device 128 of the status of a patient wearing the sensor array 101 .
- the status of the user includes, but is not limited to whether the system 100 is functioning properly, faults within the system 100 , or real time measurements from the sensor array 101 .
- the cloud 106 is considered some type of cloud computing which can be generalized as internet based computing that provides on demand shared computing processing resources and data to computer and other internet connected devices.
- the cloud 106 receives data from the electronics module 102 directly.
- data from the electronics module is transmitted to the mobile device 128 before being transmitted to the cloud 106 .
- the cloud 106 receives data from the electronics module 102 via the external monitor 104 .
- various permutations of communications initiated by the electronics module and transmitted between the external monitor 104 and the mobile device 128 results in data being transmitted to the cloud 106 .
- Data received by the cloud 106 may have already been processed by an intermediary device or can be processed on the cloud 106 and transmitted back to the intermediary device.
- the cloud 106 contains electronic medical records and data from the sensor array 101 is automatically uploaded to the electronic medical records. With real time data being uploaded to the cloud, it becomes possible to apply machine learning which can further enable automatic or semi-automatic adjustments to the electronics module 102 . Automatic updating would result in changes to the programming of the electronics module without human intervention whereas semi-automatic updating would require someone to confirm changes to the programming of the electronics module 102 .
- the cloud 106 enables examination of medical history such as pre-existing conditions and family history and machine learning can suggest or set customized thresholds and sensor sampling rates based on previous data from patients with similar conditions and data
- the previously discussed components or elements within the system 100 are intended to be exemplary rather than limiting. As the system is intended to be flexible components are able to be added and removed based on immediate needs. This includes enabling or disabling system components within one environment while enabling or disabling the same system components at a later point. For example, a facility utilizing the system for triage may not implement or enable communications to mobile device 128 while enabling communication with the cloud 106 . However, once a patient is moved from triage to a monitoring or remote monitoring environment, communication with a mobile device may be enabled. Similarly, a hospice may choose to not enable communication with the cloud 106 .
- FIG. 2A is an exemplary flowchart illustrating operations performed by various components of the system 100 to determine a risk score for sepsis, in accordance with embodiments of the invention.
- the flowchart begins with start operation 200 followed by operation 202 that initiates the sensor array.
- operation 202 occurs when electrical contact is made between the power supply in the electronics module and the working electrodes within the sensor array.
- data is received from the sensor array.
- data is received at the processor associated with the electronics module.
- the data can be viewed as being received from the electronics module at an external monitor, a mobile device or the cloud.
- Operation 206 takes the received data and stores it in a memory.
- the memory can be associated with the electronics module, an external monitor, the cloud or the mobile device.
- data from the sensor array is evaluated using the processor. Similar to storing the data, evaluation of the data can occur on the electronics module or any number of devices in communication with the electronics module such as the external monitor, the cloud or a mobile device.
- the risk score determined by operation 208 is output to operation 209 that displays the risk score.
- the risk score from operation 208 is also passed to operation 210 that determines if the risk score exceeds an alarm threshold value. If a risk score threshold value is exceeded, operation 212 outputs an alarm such as an audible, visual, tactile or combination thereof.
- Embodiments having the requisite infrastructure can enable alarms or alerting at remote locations such as, but not limited to external monitors, mobile devices and other cloud connected devices. If the risk score is below an alarm threshold, the flowchart returns to operation 204 where new data from the sensor array is received.
- FIG. 2B is an alternative embodiment of FIG. 2A that executes operation 214 after operation 210 .
- Operation 214 determines if the evaluated data is trending toward an alarm threshold. If the data is trending toward an alarm condition, operation 216 increases the data sampling rate so data is received at operation 204 at a higher rate. If the data is not trending toward an alarm condition the flowchart returns to operation 204 where additional data is received from the sensor array.
- One advantage of increasing the sampling rate is to achieve improved resolution of the rate of change of an analyte. Selectively changing the sampling rate based on real time conditions, or dynamic sampling, can be implemented in various ways because the risk score is determined from multiple analytes.
- each working electrode has a dynamic sample rate that is completely independent from the sampling rate of the other working electrodes.
- the sample rate of all of the working electrodes is dynamically tied the output of a single working electrode.
- particular metrics may be determined on data gathered at rates other than the sample rate. For example, if a rate of change of oxygen results in increased sampling rates for all analytes, the calculations for the rate of change of lactate may not be based on the increased sampling rate.
- the rate of change of lactate calculations can be based on the increased sampling rate.
- the overall sampling rate of all the electrodes can be further increased beyond the original increase for oxygen.
- the rate of change for lactate can push for higher sampling rates and the oxygen calculations can continue to be made at the original increased frequency.
- the calculations for the respective analytes may be dynamically determined on a preferred sample rate for each analyte.
- FIG. 3A-1 is an exemplary hybrid flowchart and block diagram illustrating operations and elements used to perform operation 208 that evaluates risk metrics provided by the sensor array 101 and other inputs 308 to determine a risk score, in accordance with embodiments of the invention.
- the sensor array 101 includes analyte sensors 101 a and physical sensors 101 b.
- physical sensors 101 b include, but are not limited to sensors like accelerometers and thermometers that respectively generate risk metrics such as movement and temperature.
- the analyte sensors 101 a include, but are not limited to sensors that measure risk metrics like glucose, oxygen, and lactate in real-time within subcutaneous tissue.
- a single point of entry is used to insert the analyte sensors 101 a within subcutaneous tissue.
- some physical sensors may be implanted within subcutaneous tissue while other physical sensors remain outside of the subject but still incorporated within the electronics module.
- the analyte sensors are implanted with via a single point of entry but some or all of the physical sensors are coupled with the sensor assembly concomitant with attachment of the electronics module.
- the analyte sensors 101 a are distributed among multiple separate substrates.
- the analyte sensors 101 a are disposed, or located, on a single substrate.
- operation 204 collects data from the analyte sensors 101 a and the physical sensors 101 b and in accordance with operation 206 of FIGS. 2A and 2B , stores the data into a memory.
- the physical location the memory 206 may vary between being located within the electronics module 102 , on the external monitor 103 the cloud 106 or the mobile device 116 .
- operation 208 evaluates the data to determine a risk score of developing sepsis.
- operation 208 is dependent on data collected from the sensor array 101 .
- Operation 208 can be supplemented with other inputs 308 to improve or enhance determination of a risk score, but other inputs 308 are not required to determine a risk score.
- It is the real-time measurements of glucose, lactate, and tissue oxygen risk metrics that enable determination of a risk score for developing sepsis across multiple environments.
- real-time or “substantially real-time” should be construed to mean the actual time during which something takes place, or within milliseconds so the measurement is available virtually immediately.
- a metrics processing module 300 receives sensor data that was previously stored in memory by operation 206 .
- Exemplary inputs to the metrics processing module 300 include primary inputs, or primary data, that are defined as signal data received from the sensors array for measured risk metrics such as glucose, lactate, tissue oxygen, tissue hydration, temperature and the like.
- the metrics processing module 300 allows the primary inputs to be passed through to operation 306 .
- the metrics processing module 300 also calculates secondary inputs which are defined as inputs or metrics that are calculated based on primary inputs before being input to operation 306 .
- secondary inputs include, but are not limited to ratios between primary inputs, rates of change of primary inputs, and rates of changes of ratios between primary inputs. Inclusion of secondary inputs can improve or enhance the determination of the risk score because specific changes in specific ratios of measured analytes, or primary inputs, can be an indicator of dysregulation, or the development of sepsis.
- An example of a secondary input that can be valuable in determining a risk score for sepsis is the ratio of glucose to tissue oxygen. This ratio can contribute to the risk score because an increase in glucose relative to tissue oxygen can be indicative of hypoxia, a precursor to sepsis.
- Another secondary input, the ratio of lactate to tissue oxygen is indicative of hypoxia, when there is an increase in lactate relative to tissue oxygen.
- Still another secondary input that is an exemplary precursor to sepsis is the ratio of glucose to lactate.
- a measurable increase in glucose concentration relative to lactate can be suggestive of anaerobic glycolysis, another precursor to sepsis. Accordingly, operation 300 can be summarized as receiving primary inputs (analyte sensor data and physical sensor data) and outputting to operation 306 both primary inputs and secondary inputs (metrics calculated based on primary inputs).
- Optionally supplementing operation 306 are other inputs 308 that are based or derived from external data obtained from outside the sensor array, and this can include additional risk metrics along with a subset of relative weights 310 .
- Relative weights 310 are used to modify primary, secondary and other inputs and will be discussed in more detail regarding operation 310 ′.
- Other inputs 308 are defined as risk metrics that impact a risk score that are not measured by the sensor array 101 , and may even be used to determine a risk score without any input at all from the sensor array.
- other inputs 308 may include discrete measurements of a risk metric (e.g. a one-off lab test), periodic/episodic risk metrics (e.g.
- periodic test results periodic discrete analyte(s) measurement(s) with finger pricks, etc.
- continuous real-time measurements from supplemental medical monitors such as heart rate, blood pressure, or even peripheral oxygen saturation rates using non-invasive pulse oximetry as an approximation of the more accurate invasive measurement of tissue oxygen via the sensor array 101 .
- supplemental medical monitors such as heart rate, blood pressure, or even peripheral oxygen saturation rates using non-invasive pulse oximetry as an approximation of the more accurate invasive measurement of tissue oxygen via the sensor array 101 .
- other inputs 308 include, but are not limited to data or metrics commonly available from lab/clinical tests, or continuously collected through readily available hospital monitoring equipment. If enabled, some embodiments receive other inputs 308 from electronic medical records stored in cloud 106 . Alternatively, a GUI associated with a monitor or mobile device can be used to supply other inputs 308 .
- other inputs 308 include risk metrics such as, but not limited to heart rate, respiratory rate, urine volume, blood pressure, cognitive/neurological assessment scores, and age.
- risk metrics such as, but not limited to heart rate, respiratory rate, urine volume, blood pressure, cognitive/neurological assessment scores, and age.
- other inputs 308 that are based on measured values like the sample above, some embodiments of other inputs 308 enable calculations of rates of change and ratios between various other inputs. For example, rates of change of heart rate and rates of change of blood pressure.
- Other inputs 308 can further include any disease states of a subject along with any associated comorbidity risk factors.
- Inclusion of disease states or particular chronic illnesses further enhances the ability to determine a meaningful risk score of developing sepsis, and the following chronic disease states listed in decreasing order of risk, can contribute to an increased risk of developing sepsis: AIDS, liver failure, cancer, and generally immune compromised patients.
- Operation 306 receives risk metrics in the form of primary and secondary inputs from the metrics processing module 300 along with any other inputs 308 and transforms and normalizes the various inputs into risk values that are functions of the original risk metrics.
- the risk values are a number between zero and one where one is a high risk for developing sepsis and zero is a low risk for developing sepsis.
- When transforming and normalizing primary and secondary inputs one embodiment looks for deviations from baselines to determine a risk value.
- the risk value is determined by comparing measured primary and secondary inputs to threshold values. The transformation and normalization performed by operation 306 converts individual risk metrics to unitless risk values that enables comparison and relative weighting to be applied across the risk values.
- the output of operation 306 the risk values between zero and one, are input into operation 302 that stores the risk values into a risk index.
- the risk index is defined as a compendium of all of the transformed and normalized risk values. Storage of the risk values within the risk index enables any or all of the individual risk values to be displayed in operation 312 . Display of individual risk values can help provide context to a health care provider regarding particular risk metrics within the risk score. For example, inclusion of the risk index enables operation 312 to display lactate trends for a subject which can further provide context and insight into the behavior of the risk score. Without storage of the risk values within the risk index, a healthcare provider may only be able to see the end result risk score without context of the risk values. This could lead a healthcare provider to speculate the cause of the risk score behavior rather than simply being able to see changes in the risk values over time on a display.
- a next operation 303 determines if relative weights are applied to the risk values within the risk index. If relative weights are not applied, operation 304 determines the risk score by taking the sum of the risk values. If relative weights are applied, operation 310 ′ applies relative weights 310 to appropriate risk values before operation 304 then calculates a weighted average risk score.
- associating a relative weight to specific risk metrics affected by particular pre-existing or chronic condition such as diabetes, cancer, leukemia or other immune-compromised condition enables emphasis or de-emphasis of single, multiple, or all primary, secondary and other inputs.
- FIG. 6 is a table of exemplary relative weights that can be applied to various risk metrics when a system is applied in a triage environment for a non-diabetic subject and a diabetic subject. As shown in FIG. 6 , the relative weights of zero ensures that the greater variations in glucose measurements from a diabetic subject do not influence determination of the risk score in triage mode. However, the autoimmune disorder relative weight of three may result in an overall more conservative determination of a risk score. FIG. 6 is intended to be an exemplary illustration of how relative weights can be used to influence different primary and secondary metrics used to determine the risk score of developing sepsis. Other chronic disease states may require different relative weights based on how the disease state impacts a particular metric.
- relative weights 310 can also be customized or tailored to be specific to a particular hospital, health system, physician or patient need.
- the relative weights 310 may be customized to better fit a particular hospital workflow such as where a hospital intensive care unit already utilizes sepsis scorecards that assign different relative weights to various lab/clinical tests.
- the relative weights 310 for the system can be customized to follow similar, if not exact matches to the existing sepsis scorecards.
- the relative weights can be adjusted based on the whether the patient is in a triage, patient monitoring or remote monitoring environment.
- FIG. 7 includes a table of exemplary relative weighting coefficients that can be applied to various risk metrics based on the subject's environment.
- operation 304 The output of operation 304 , the risk score, is used as input into operation 210 that determines if the risk score is greater than an alarm threshold and the flowchart is completed as shown in FIGS. 2A and 2B .
- operation 208 is capable of providing output to a display on a hospital monitor, mobile device, or other screen based on output from either operation 302 of the risk values within the risk index and/or the risk score from operation 304 .
- operation 312 is intended to display visual representation of real-time and/or historical data such as the risk score or individual risk values from within the risk index. For example, in some embodiments, particularly those in the patient monitoring environment, real time charts of the measured analyte data are shown on a display 312 in addition to a final risk score.
- a simplified display showing the resulting risk index is displayed on a mobile device such as a smartphone.
- additional data such as real time charts from the chemical sensors may be displayed for the physician. The ability to display individual risk values can provide meaningful insight to physicians and medical staff regarding changes, or lack of changes to the risk score.
- FIG. 3A-2 is an exemplary hybrid flowchart and block diagram further including the application of conditional logic or conditional weights, in accordance with embodiments of the invention.
- the ability to include conditional logic allows use of prior outputs as input thereby enabling more complex methods to determine a risk score.
- Differentiation between FIG. 3A-1 and FIG. 3A-2 manifest when operation 303 determines that relative weighting is applied to the risk values.
- the relative weights 310 are carried into operation 350 that determines if a conditions, or conditions, have been satisfied.
- the condition, or conditions are drawn from anything measured by, or input into the system or stored in the system memory.
- conditions may be applied to primary or secondary inputs, risk values or a previously determined risk score. Failure to meet a condition can results in adjustments being made to a single relative weight for the single risk value, adjustments to the relative weights for other risk values, or adjustment to the relative weights of all the risk values.
- condition for risk values associated with oxygen, impedance, rate of change of temperature there are conditions for risk values associated with oxygen, impedance, rate of change of temperature.
- the condition for oxygen is not met resulting in an adjustment being made to a relative weight.
- the relative weight being adjusted can be for oxygen, impedance, rate of change of temperature or any other primary, secondary input, risk value or even previously determined risk score.
- Additionally embodiments include conditions that are chained, like a conditional tree with branches for decisions points. For example, if oxygen and glucose risk values hit independent target thresholds, make an adjustment to the relative weighting factor for lactate.
- the particular conditions and changes to relative weights discussed above are intended to be exemplary rather than comprehensive. Other conditions, or combinations of conditions can drive changes to the relative weights to further improve the determination of the risk score.
- operation 360 adjusts the relative weights 310 before passing the adjusted relative weights to operation 310 ′′ that applies the adjusted relative weights to the risk values. If the condition or conditions of operation 350 are satisfied, operation 310 ′′ applies the unadjusted relative weights 310 to the risk values. In a later operation, 304 , the risk score is determined based on risk values untouched by relative weights from operation 303 , or risk values that have been adjusted with either adjusted relative weights or original relative weights.
- FIG. 3B is a hybrid flowchart and block diagram illustrating exemplary operations within the metrics processing module 300 , in accordance with embodiments of the invention.
- Operation 300 - 2 starts processing primary data that enters the metrics processing module 300 .
- Subsequent operation 300 - 4 applies noise detection and operation 300 - 6 applies smoothing filters, to the primary data within the metrics processing module 300 .
- the output from operation 300 - 6 is passed to operation 300 - 8 that uses smoothed primary data to determine rate estimations or the first type of secondary input or secondary data.
- rate estimations from operation 300 - 8 are used by operation 300 - 10 to determine predictive values.
- the output of operations 300 - 6 , 300 - 8 and 300 - 10 are also provided to operation 300 - 12 that performs a first signal transformation.
- the signal transformation includes, but is not limited to calibration or utilization of look-up tables to transform or translate the respective signals into relevant units.
- primary input such as glucose data enters operation 300 it may be in the form of measured current from the working electrode of the multianalyte sensor.
- the original current measurement is transformed or translated into an instantaneous concentration of glucose in units such as millimole of glucose.
- instantaneous measurements of primary inputs glucose, lactate, and tissue oxygen help determine if conditions within the subject are indicative of sepsis when the measurements deviate significantly from normal ranges.
- the metrics processing module 300 is also capable of looking at measurements over windows of time, or the rates of change of primary inputs, and provide additional insight or even a predictive capability for detecting conditions that can lead to the onset of sepsis. For example, rates of change of data measured by the sensor array and passed through both operations 300 - 8 and 300 - 12 result in the rates of change of lactate, glucose and tissue oxygen. Additionally, predicted measurement of glucose, lactate and tissue oxygen are also output if data passes through operations 300 - 10 and 300 - 12 .
- a projection in time can be achieved by calculating a trend from recent glucose concentrations values, or in one embodiment, the change of glucose measurement over time, or more simply, the glucose derivative.
- a common method to estimate the glucose derivative is to apply convolution (i.e. Savitzky-Golay filtering algorithm) to the data.
- future glucose measurement are estimated using more advanced algorithms that additionally use the noise content of the signal as an input to compute the prediction (i.e. a Kalman filter).
- the predicted value may be included as a risk metric when determining the risk score for the onset of sepsis.
- any predicted value can be adjusted appropriately via relative weight 310 that can be applied to adjust risk scores.
- the relative weight for predicted glucose may be lower than the relative weight for instantaneous glucose measurements.
- the relative weights for the various data points and rates of change may be tuned to optimize for either certainty or predictive capability.
- Another indicator or signal of the onset of sepsis is lack of glycemic control.
- a time-in-range calculation or a time-out-of-range metric normalized to a percentage of the evaluated window time is used as a metric to reflect the ability of the patient to manage glucose concentrations.
- Glycemic control unlike the previously discussed trend and predictive data, is a trailing indicator and requires significantly more time (i.e. data points) before a reasonable calculation can be made.
- the glycemic control metric may require hours, or even multiple days' worth of data points instead of the minutes of data required for predictive metrics. Accordingly, effective use of a glycemic control metric may be found when the system is utilized in an outpatient setting to monitor trends over extended periods of time.
- lactate concentrations are a marker for sepsis and the onset of sepsis. Conversely, decreasing oxygen saturation is also associated with an increased risk of sepsis. Following the same methods described above for glucose, trending data for lactate concentrations may similarly be calculated to support acute prediction/diagnosis of sepsis. Likewise, calculation of oxygen saturation rate of change should follow the same algorithms used for glucose and lactate. However, unlike glucose, naturally decreasing lactate concentration, or clearance of lactate, by the body is a signal of decreasing risk of sepsis. Thus, a negative lactate rate of change would represent one of the few negative risk values. Similarly, elevated lactate concentrations coinciding with regular or faster than regular lactate clearance may not be considered cause for alarm because the subject continues to clear lactate from the body at a regular or above regular rate.
- FIG. 4A is an exemplary chart illustrating how temperature risk metrics are converted to normalized temperature risk values, in accordance with embodiments of the invention.
- immune response typically results in an initial increase in body temperature.
- hypothermia becomes a possibility.
- hypothermia or hyperthermia deviation from normal body temperature is associated with increased risk of mortality.
- normothermia is centered around 37 Celsius and is associated with a very low risk value.
- the temperature risk value begins to increase toward a value of one.
- FIG. 4B is an exemplary chart illustrating conversion of lactate sensor readings to normalized lactate risk values, in accordance with embodiments of the invention.
- Normal plasma lactate concentration is 0.5 to 1.5 milliequivalents per liter.
- Lactic acidosis is generally defined as a plasma lactate concentration greater than 4 milliequivalents per liter, even in the absence of overt academia.
- sepsis the inability of the body to support lactic acid clearance results in increased levels of lactate, as high as 20 milliequivalents per liter.
- the lactate risk value increases sharply upon exceeding 2.0 milliequivalents per liter and reaching a maximum of 1 after the lactate concentration approaches limits outside of lactic acidosis.
- the maximum relative weighting factor can be limited to 0.5 rather than 1 for lactate concentrations between four and six milliequivalents per liter.
- the change of lactate risk value based on exercise occurs automatically when a physical sensor measuring movement detects continuous motion associated with exercise.
- Other modifications to the lactate risk value chart can be made based on other inputs such as, but not limited to chronic disease states and certain types of medication.
- FIGS. 4C and 4D are exemplary charts illustrating how glucose risk values can change in accordance with embodiments of the invention.
- the American Diabetes Association defines tight glucose control is achieved between the range of 3.9-7.2 millimol/L (70-130 mg/dL). Deviations outside of this range are correlated with long-term health effects typically associated with diabetes mellitus. Similarly, in the intensive care unit setting both hypoglycemia and hyperglycemia are associated with increased mortality with hypoglycemia carrying a greater risk of death. In the case of sepsis, an argument can be made to exclusively track hyperglycemia because sepsis is correlated with elevated glucose levels.
- FIG. 4C is an exemplary chart of glucose risk values that places a greater risk of developing sepsis on hyperglycemia.
- the risk index can further include consideration of hypoglycemia. Consideration of hypoglycemia can result in a glucose risk value chart similar to that found in FIG. 4D where the glucose risk value approaches or is equal to zero around the tight glucose control range of 70-130 mg/dL. In still further embodiments, a log-normalized approach can be considered to generate a more evenly matched relative weights between hypoglycemia and hyperglycemia. FIGS. 4C and 4D further illustrate how conversion and normalization of risk metrics to risk values are customizable based on hospital protocols, physician preferences, or other considerations.
- FIG. 4E is an exemplary chart of risk values associated with a secondary input, specifically, a rate of change of lactate, in accordance with embodiments of the invention.
- lactate trending data may be determined to support acute diagnosis or prediction of sepsis.
- decreasing lactate concentration being a signal of decreasing risk of sepsis and corresponding negative risk value.
- FIG. 5 is an exemplary flowchart illustrating integration of the system within a therapy management system to enable a feedback mode in accordance with embodiments of the invention.
- Feedback mode is intended to monitor the effects of any treatment protocol and provide real-time, actionable information to external control algorithms whose aim is to optimize the management of therapy delivery to subjects with sepsis or a high risk of developing sepsis. This is accomplished by modifying therapy based on system output achieving targets and/or setpoints for specific risk metrics based on a specific clinical protocol. For example, if the clinical protocol is early goal directed therapy, feedback mode enables automatic or semi-automatic adjustments to the therapy based on the output of the system.
- Operation 500 initiates feedback mode assuming the subject is already being monitored by the system and a decision has been made to initiate a therapy which is executed by operation 502 .
- Various forms of therapy for sepsis include, but are not limited to fluid resuscitation or infusion of dobutamine.
- data from the system such as the risk score, along with real-time sensor values and rates of change in sensor values is gathered and used as input for the next operation.
- operation 506 determines error in the input versus the targets and setpoints associated with the therapy.
- Operation 508 inputs the error from operation 506 into a controller that in operation 510 determines if changes to the therapy is needed.
- the system can notify a healthcare provided of suggested changes.
- the system is enabled to make changes to therapy parameters such as infusion rates and the like. If the therapy protocol is within the targets or setpoints so no changes are recommended, operation 510 the flowchart returns to operation 504 .
- the therapy management system described above incorporates a feedback loop.
- Other embodiments of the therapy management system can be further enhanced or improved with the addition of adaptive control. For example, in an embodiment employing adaptive control, if elevated lactate levels coincide with an increasing lactate clearance rate above a specified threshold, the risk score can be determined without taking into account the elevated lactate levels.
- the system is intended to be used in a variety of modes such as, but not limited to triage, monitoring, and remote monitoring each optionally supplemented by a feedback mode.
- Triage mode is intended to rapidly determine if a patient is afflicted with sepsis.
- the monitoring mode is intended to either monitor progress of a septic patient or provide notification if a patient is potentially developing sepsis.
- the remote monitor mode is intended to leverage mobile technology and cloud based communications to provide early notification of the potential development of sepsis in high-risk patients away from traditional medical or care facilities.
- the particular embodiments discussed above are exemplary embodiments of the system and should not be construed as the explicit limits of the system.
- inventions of the invention include separately or together, both detection and disease management based on continuous real time monitoring of multiple analytes indicative of disease states or medical conditions.
- the system is adaptable to monitor the effectiveness of treatments such as, but not limited to chemotherapy.
- treatments such as, but not limited to chemotherapy.
- real time monitoring of metabolic activity near the tumor can provide insight of the efficacy of treatment.
- the system is further adaptable to provide real time measurements and monitoring of analytes that are indicative of metabolic conditions and disease states associated therewith.
- embodiments of the invention can also be used to monitor for conditions indicative of cancer in light of the following pathophysiological for some types of cancer.
- High energy metabolites such as ketones and lactate are associated with accelerated tumor growth and tumor metastases.
- increases in anabolic tumor growth rates are associated with upregulated mitochondrial metabolism which often are the byproduct of increases in circulating oxygen.
- Warburg effect describes the increased conversion to glucose to lactate even in the presence of normal to high levels of circulating oxygen.
- the energetically inefficient nature of the Warburg effect drives increases in glucose uptake through signaling pathways that ultimately leads to increases in insulin resistance and a concomitant increase in circulating glucose.
- the complex interplay amongst metabolic pathways associated with cancer cells suggest a continuous monitor capable of measuring ketones, oxygen, glucose, and lactate can be used to monitor those at risk for cancer, those who are being treated for cancer, and those who are at risk for cancer recurrence.
- the continuous measurement of metabolites, their rates of change, and their relative concentrations can be analyzed through algorithms that serve to simulate or model the pathophysiological processes associated with tumor or cancer cell growth in order to identify individuals whose cancer risks have markedly increased and to then alert members of the care team through wired or wireless communication methods who can then initiate the appropriate intervention.
- a cancer monitoring system such as the one described above can also be used to monitor the effectiveness of a range of treatments and may in fact be used to enable more effective continuous treatment as opposed to the episodic or periodic protocols that tend to be reactive and as a result less effective in regards to treatment efficacy.
- the system is configurable to measure reactive oxide molecules such as, but not limited to nitric oxide and superoxide.
- reactive oxide molecules such as, but not limited to nitric oxide and superoxide.
- reactive oxide molecules are often overexpressed. Overexpression of reactive oxide molecules can cause the disruption of processes in the mitochondria and may have a role in mitochondrion dysfunction.
- Monitoring or detecting reactive oxide molecules and superoxide in relation to inflammation can be valuable within a hospital because of the strong indication for infection, regardless of patient profile.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Signal Processing (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
An apparatus for early detection of sepsis in a host is disclosed. The apparatus includes a first sensor to directly measure a glucose level, a second sensor to directly measure a lactate level and a third sensor to directly measure a tissue oxygen level. The first sensor, the second sensor, and the third sensor all being inserted at a single point of entry in a subcutaneous space of the host such that a predetermined correlation between the glucose level, lactate level, and tissue oxygen level signals conditions related to sepsis.
Description
- This application is a continuation application that claims the benefit under 35 U.S.C. 120 of U.S. patent application Ser. No. 15/417.055 filed Jan. 26, 2106, which claims priority under section 119(e) from U.S. provisional application Nos. 62/336,482, filed May 13, 2016; 62/348,806, filed Jun. 10, 2016; 62/353,559, filed Jun. 23, 2016; 62/370,226, filed Aug. 2, 2016; 62/383,233, filed Sep. 2, 2016; 62/401,481, filed Sep. 29, 2016; and 62/443,070 filed Jan. 6, 2017. The applications listed above are hereby incorporated by reference in their entireties for all purposes.
- The invention generally relates to systems and methods for real time metabolic monitoring to enable diagnosis and monitoring of disease progression including risk assessment, diagnosis, treatment and monitoring of sepsis. More specifically, the invention relates to the use of sensors and related electronics in conjunction with algorithms and software for the early identification and warning before the onset of sepsis.
- Sepsis is a medical condition that is the result of a severe inflammatory response to a circulation infection. Current estimates suggest that approximately one-million Americans will develop sepsis on an annual basis and between 30 and 50 percent of those patients will succumb due to sepsis related complications such as multi-organ failure. The economic burden of sepsis is significant with recent estimates suggesting yearly in patient costs well in excess of $22 billion.
- The economic burden of sepsis is expected to increase dramatically in the coming years given the increasing prevalence and incidence of sepsis due in large part to both increased life expectancy and an increase in antibiotic resistant bacteria. The costs associated with treating sepsis are significant in part due to the intensive care unit (ICU) as being the primary venue for highly invasive early goal directed treatment (EGDT) strategies that use the output of centrally placed catheters capable of measuring arterial pressure in comparison to a goal to modify or modulate the use of intravenous fluids, oxygen, drugs and blood transfusions in what can be a futile fight for survival. Those who recover from a sepsis infection may never actually completely recover, resulting in large indirect costs associated with sepsis recovery that further burdens an already burdened healthcare system.
- A randomized control trial (RCT) published in 2001 showed via a single-site, EGDT administration of a hemodynamic driven protocol for six hours following diagnosis and triage resulted in a reduction of in-hospital mortality from 46.5% to 30.5% and evolved into the standard of care and has been included in the six-hour sepsis bundle protocol used by many hospitals. A larger RCT named Protocol Care for Early Septic Shock (ProCESS) sought to replicate the previously discussed results within a larger population enrolled across a large number of diverse academic hospital emergency departments. The ProCESS trial demonstrated no improvement in 60-day survival rates between the EGDT and normal care cohort. Interestingly, the overall mortality rate within all cohorts of the ProCESS clinical trial group was approximately 21% (˜30% at 90 days), which was substantially lower than in hospital mortality rate documented in the previous study thereby suggesting improvements in nominal sepsis related care.
- A study similar to ProCESS named Protocolized Management in Sepsis (ProMISe) conducted in the United Kingdom showed no difference in the survival at 90 days between the EGDT and control group. The 90-day mortality rate associated with the ProMISe group was approximately 29%, a number quite similar to that observed during the ProCESS trial. The results associated with the two recently run large clinical trials strongly suggest little incremental benefit associated with current approaches to EGDT; however, the high mortality rates (˜30%) at 90 days suggest a critical need for better therapeutic protocols.
- Of note in both the ProCESS and ProMISe trials is the high level of admission lactate concentration associated with the baseline or admission blood sample analysis. Average lactate concentration for the two study populations was 2.5-3.5× a high normal level of 2 mM. Fuller and Dellinger have proposed that lactate and lactate clearance be used instead of, or in conjunction with, mixed venous oxygen saturation as an endpoint in any quantitative or goal directed resuscitation protocol applied to critical illness such as sepsis. Their review of the literature strongly suggests that therapeutic interventions that successfully drive lactate clearance is directly related to reduced mortality.
- The claimed invention seeks to address timely and cost effective methods and systems to diagnose sepsis. In many examples discussed below multiple analytes and physical parameters are monitored. In other examples, diagnosis is based on monitoring multiple analytes without physical parameters. While embodiments and examples may be related to particular analytes and physical parameters, the scope of the disclosure and claims should not be construed to be limited to the specifically addressed analytes and parameters. Rather it should be recognized that additional or other analytes and physical parameters can be monitored to assist in the detection and diagnosis of sepsis.
- In one embodiment a system to enable risk assessment of the onset of sepsis is disclosed. The system includes a sensor array for insertion within subcutaneous tissue for continuous monitoring of at least two analytes that are indicators of the onset of sepsis. Further included within the system is an electronics module that includes a power supply, a processor, memory, and a bi-directional communications module. In one embodiment the electronics module is configured to couple with the sensor array while a power supply powers the sensor array and a processor is in communication with the sensor array. The processor calculates a risk index for the onset of sepsis based on characteristics of the at least two analytes being continuously monitored. The risk index being transmitted to and stored on a computer readable electronic health record.
- In another embodiment, an apparatus for early detection of sepsis in a host is disclosed. The apparatus includes a first sensor to directly measure a glucose level, a second sensor to directly measure a lactate level and a third sensor to directly measure a tissue oxygen level. The first sensor, the second sensor, and the third sensor all being inserted at a single point of entry in a subcutaneous space of the host such that a predetermined correlation between the glucose level, lactate level, and tissue oxygen level signals conditions related to sepsis.
- In still another embodiment, a method for the early detection of sepsis in a host is disclosed. The method includes an operation that inserts via a single point of entry a sensor assembly having a first sensor, a second sensor and a third sensor into subcutaneous tissue of the host. The method continues with an operation to measure a glucose level using the first sensor. An additional operation measures a lactate level using the second sensor, while still an additional operation measures tissue oxygen level using the third sensor. A subsequent operation determines a risk index for sepsis based on predetermined correlations between the glucose level, the lactate level and the tissue oxygen level.
- In another embodiment, a method for the early detection of cancer is disclosed. The method includes a first operation of inserting a sensor assembly having a first sensor and a second sensor via a single point of entry into subcutaneous tissue. Other operations measure a first analyte level with the first sensor and a second analyte level with the second sensor. The second analyte being different than the first analyte. The method further determines a risk index for cancer based on predetermined correlations between the levels of the first analyte and second analyte. Wherein the first analyte and second analyte are selected from a group consisting of glucose, lactate, oxygen or a ketone.
- Another embodiment discloses a method to monitor for a medical condition that includes an operation that identifies at least two different biological markers relevant to the pathophysiological process of the medical condition. A later operation enables at least two sensors to measure the at least two identified biological markers. A later operation configures the sensors onto a sensor array that is applied at a single site and another operation monitors the biological markers for pathophysiological conditions indicative of development of the medical condition.
- Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, various features of embodiments of the invention.
-
FIG. 1A is an exemplary block diagram showing components within a system to determine a risk score of developing sepsis, in accordance with embodiments of the invention. -
FIGS. 1B-1 and 1B-2 are exemplary isometric views ofsensor array 101, in accordance with embodiments of the invention. -
FIG. 2A is an exemplary flowchart illustrating operations performed by various components of the system to determine a risk score for sepsis, in accordance with embodiments of the invention. -
FIG. 2B is an alternative embodiment ofFIG. 2A , in accordance with embodiments of the invention. -
FIG. 3A-1 is an exemplary hybrid flowchart and block diagram illustrating operations and elements used to perform an operation that evaluates data to determine a risk score, in accordance with embodiments of the invention. -
FIG. 3A-2 is an exemplary hybrid flowchart and block diagram further including the application of conditional logic or conditional weights, in accordance with embodiments of the invention. -
FIG. 3B is a hybrid flowchart and block diagram illustrating exemplary operations within the metrics processing module, in accordance with embodiments of the invention. -
FIG. 4A is an exemplary chart illustrating how temperature risk metrics are converted to normalized temperature risk values, in accordance with embodiments of the invention. -
FIG. 4B is an exemplary chart illustrating conversion of lactate sensor readings to normalized lactate risk values, in accordance with embodiments of the invention. -
FIGS. 4C and 4D are exemplary charts illustrating how glucose risk values can change, in accordance with embodiments of the invention. -
FIG. 4E is an exemplary chart of risk values associated with a secondary input, specifically, a rate of change of lactate, in accordance with embodiments of the invention. -
FIG. 5 is an exemplary flowchart illustrating integration of the system within a therapy management system to enable a feedback mode in accordance with embodiments of the invention. -
FIG. 6 includes a table of exemplary triage mode relative weight coefficients for patients with and without diabetes, in accordance with embodiments of the invention. -
FIG. 7 includes a table of exemplary relative weighting coefficients for particular metrics, in accordance with embodiments of the invention. - Simultaneous continuous or periodic measurement of physical parameters and chemical entities as a means of measuring disease progression or inflection that requires timely clinical intervention can be extended to a multitude of disease states and may include multiple measurement modalities. The design of such medical monitoring systems requires an understanding of the pathophysiological processes associated with a particular illness or disease. From this basic understanding, a number of small molecules, biological markers of disease, and physiological measures with high diagnostic and prognostic value for a particular disease and/or condition can be identified. Sensors that rely on physical, electrochemical, and optical transducers can be functionalized to directly or indirectly measure the small molecules, biological markers, and physiological measures associated with a specific disease. Advanced manufacturing techniques can then be used to integrate the sensors in question into a multi-analyte or multi-parameter that can be deployed invasively or noninvasively within a target population. Software algorithms that combine an understanding of disease, artificial intelligence, and machine learning can be embedded in the instrumentation or systems that power and acquires data from a disease specific multi-parameter sensor to assess the cellular and/or systemic progression of condition or disease. Configurable alerts and alarms associated with the medical monitoring system can be communicated through wired and wireless methods to enable timely therapeutic intervention in order to derive the benefits of proactive disease or illness management.
- Disclosed below is a robust system that performs real-time simultaneous continuous monitoring of specific risk metrics to generate a risk score for developing sepsis. The risk score for developing sepsis is determined using risk metrics based on data obtained from (i) sensors placed implanted within or associated with a subject and/or (ii) other external input available on the subject (such as electronic medical records, test data from hospital/clinic measurements where the subject is being evaluated, or has been evaluated previously, for a medical condition). Risk metrics based on sensor data can be based on continuous and substantially real-time monitoring of analytes and physiological parameters relevant to sepsis. In one embodiment, the risk metrics includes, but is not limited to analytes such as, glucose, tissue oxygen and lactate. Detectable changes in those risk metrics can be indicative of a localized infection progressing towards sepsis. For example, the pathophysiological processes of a localized infection developing into sepsis and the relationship between glucose, lactate and tissue oxygen is described below. As a localized infection initially begins progressing toward sepsis there can be a rapid increase in insulin resistance that results in a measurable increase in glucose. Undetected and untreated the infection can continue to progress towards sepsis where the measureable increase in glucose eventually begins coinciding with a measureable decrease in tissue oxygen. Further progression toward sepsis results in decreased tissue oxygen coinciding with an increase in lactate levels and highly elevated lactate level, in conjunction with other factors, can be indicative of a septic infection. Accordingly, analysis of continuous real time measurements of glucose, lactate and tissue oxygen in light of the pathophysiological process described above enables determination of a risk score of developing sepsis.
- In a simple embodiment the risk score is determined based on a sum of normalized primary inputs, where primary inputs are sensor measured concentrations of analytes such as, but not limited to, glucose, tissue oxygen and lactate. A more refined risk score is determined by incorporating secondary inputs, which are risk metrics that are calculated based on primary inputs. Examples of secondary inputs include, but are not limited to rates of change of glucose, tissue oxygen and lactate. In a variation of this embodiment, the risk score additionally incorporates looking at measured inputs over time differently. For example, rather than using the same time window for all evaluations, each analyte or metric is examined at a preferred frequency. Relative weighting factors can also be applied to either or both primary and secondary inputs to emphasize or deemphasize particular risk metrics when determining a risk score. Sources for relative weighting are found in personal health records such in measured or calculated metrics or be derived from personal health records. An example of relative weighting derived from measured metrics includes, but is not limited to decreasing the influence of high lactate concentrations when coincident with nominal lactate clearance rates. An example of relative weighting derived from personal health records is increasing weighting for all metrics when a subject is immunocompromised.
- The system is configurable for use in a variety of environments including, but not limited to triage, patient monitoring and remote monitoring, where each mode may be further supplemented with a feedback/treatment mode. In a triage environment the system determines a risk score that can help determine if a patient may have developed sepsis. In a patient monitoring environment, the risk score and changes to the risk score over time enables both automated evaluation if a patient may be trending toward developing sepsis and automated evaluation of efficacy of therapy for patients known to be septic. In a remote monitoring environment, the risk score enables monitoring of patients for early warning signs indicative of the onset of sepsis.
- Within the triage environment the system is applied to a patient entering a medical facility such as, but not limited to an emergency room, an urgent care clinic or a mobile medical emergency environment such as an ambulance or helicopter. Other alternative triage environments include locations with elevated numbers of high risk individuals such as elder care facilities, nursing homes and hospice facilities. In triage environments the system is intended to rapidly determine a risk score for sepsis based on risk metrics that are indicative of an existing sepsis condition. This enables initiation of goal directed therapy for the treatment of sepsis within a minimal amount of time.
- If a patient is found to be septic, the system is capable of transitioning from a diagnostic tool to a monitoring device capable of providing data to assist in evaluating the efficacy of ongoing therapy. Assuming a triage patient is deemed to not be septic, the system can transition to a patient monitoring mode where the objective is to output a risk score that provides notification that a patient is trending toward conditions indicative of sepsis.
- Applied within a patient monitoring environment, the system enables monitoring of septic patients, continued analysis of data from triage patients and further includes monitoring of postoperative patients. In many embodiments the patient monitoring environment is an ambulatory patient within a medical care facility such as a hospital or an outpatient clinic. Regardless of the type of facility, for patients afflicted with sepsis, the system can provide real time continuous monitoring of analytes that are indicative of the efficacy of ongoing therapy. The real time continuous data can enable more frequent and responsive changes in goal directed therapy. For example, rather than having to wait for discrete lactate samples to be returned from a laboratory, with real time continuous monitoring physicians can easily see if lactate levels are increasing or decreasing and additionally the rate at which lactate levels are changing. With rate of change data, physicians can change and modify treatment protocols and see the results of previous changes more rapidly than with discrete samples that may take hours to return from the laboratory.
- For patients without sepsis the system continues to generate a risk score for developing sepsis with the objective of providing notification that a patient may be trending toward conditions indicative of sepsis. When the system provides notification a patient is trending towards a condition indicative of sepsis various care protocols may require increased monitoring of the patient. Alternatively, updated care protocols may proscribe early intervention and application of goal directed therapy to halt further trending towards sepsis that minimize the likelihood of the patient continuing to trend toward sepsis.
- In a remote monitoring environment, the system can further be transitioned from a medical care facility to a mobile monitor capable of operating as a home monitor or any other location outside of a medical care facility. Use of the system as a mobile monitor may be desirable for patients being discharged from a medical facility that may be considered high risk to develop sepsis such as an elderly postoperative patient. In another embodiment, the remote monitoring capability of the system can be expanded to generally high risk individuals such as those with compromised immune systems, and those living in elder care, nursing homes or hospice facilities.
- The goal for remote monitoring is to provide early notification that a patient is trending toward a condition indicative of sepsis. In many of these embodiments it may not be desirable to monitor lactate while scrupulously monitoring rates of change of glucose and oxygen. In some embodiments of remote monitoring, the notification is provided to the patient while in other embodiments the notification is provided to an attending physician. In still other embodiments, notification is provided to both the patient and at least one medical or care professionals such as, but not limited to an attending physician, nurse, resident healthcare provider, or a centralized care facility that can contact EMS. Similar to patient monitoring use of the system as a remote monitor can result in a patient seeking more timely application of goal directed therapy that containing an infection to a localized system and minimizes the likelihood of the infection becoming systemic.
- Optionally enhancing each of the previously described modes for the system is feedback/treatment mode. Feedback mode is intended to monitor the effects of any treatment protocol and provide real-time, actionable information to external control algorithms whose aim is to optimize the management of therapy delivery to subjects with sepsis or a high risk of developing sepsis. In many embodiments, this is accomplished by modifying therapy based on system outputs achieving targets and/or set points for specific risk metrics based on a specific clinical protocol.
-
FIG. 1A is an exemplary block diagram showing components within asystem 100 to determine a risk score of developing sepsis, in accordance with embodiments of the invention. Broadly, thesystem 100 includes asensor array 101 that includesanalytes sensors 101 a andphysical sensors 101 b powered by anelectronics module 102 that further enables bi-directional communication with a plurality of remote devices, such as, but not limited to anexternal monitor 104,cloud computing systems 106 andmobile devices 128. The remote devices enable different aspects of functionality of thesystem 100, such as, but not limited to entry of patient specific data, display of historical and trending data acquired by thesystem 100, and machine learning. The totality of components shown inFIG. 1A enable thesystem 100 to be used across a variety of environments such as triage, patient monitoring and remote monitoring. However, embodiments tailored for a specific environment may not include all of the components shown inFIG. 1A . For example, use of thesystem 100 as a remote monitor in a home may not utilize anexternal monitor 104. Likewise, when thesystem 100 is used as a patient monitor in a hospital environment, thesystem 100 may not include amobile device 128. The inclusion of all of the components withinFIG. 1A is intended to illustrate the flexibility and adaptability of thesystem 100 to be used in different environments. However, regardless of environment, an element of thesystem 100 that is required for all embodiments is thesensor array 101. -
FIGS. 1B-1 and 1B-2 are exemplary isometric views ofsensor array 101, in accordance with embodiments of the invention. At a minimum, thesensor array 101 includes a plurality of analyte sensors such as, but not limited to sensors configured to continuously measure glucose, lactate and oxygen or combinations thereof. The respective analyte sensors are formed eitherfirst sensor assembly 1001 orsecond sensor assembly 1002 that are placed or coupled with asensor carrier 1003.Sensor carrier 1003 includesarea 1005 that is configurable to receive physical sensors, such as, but not limited to thermometers, accelerometers and the like. Insertion hollow 1004 running through thesensor carrier 1003 enables insertion of thesensor array 101 via a single point of entry using an insertion sharp such as, but not limited to a needle. After insertion of thesensor array 101 the insertion sharp is withdrawn leaving insertion hollow 1004 empty. The insertion hollow 1004 can optionally be utilized to place additional physical sensors within the subject such as, but not limited to a discrete tissue fluid monitoring sensor, e.g. a subcutaneous tissue impedance measurement system. - In some embodiments the
sensor array 101 includes a combination of any two of glucose, lactate and oxygen sensors. In other embodiments, the sensor array includes 101 includes at least one each of glucose, lactate, and oxygen sensors. In many embodiments, the respective sensors for glucose, lactate and oxygen are electrochemical sensors that include multiple electrodes or transducers that are dispersed along and/or amongfirst sensor assembly 1001 andsecond sensor assembly 1002. For example, the glucose sensor can include a single or multiple glucose measuring electrodes found on either first orsecond sensor assemblies - The
sensor array 101 further includes additional sensors or abilities to measure physical characteristics such as, but not limited to movement (via accelerometers), temperature, tissue impedance (such as tissue hydration levels related to development of edema), skin impedance and sensor hydration levels. The specific physical sensors discussed should not be construed as limiting. Other and additional physical characteristics from physical sensors associated with thesensor array 101 can be used as risk metric inputs to the risk score. Monitoring hydration levels of at least one some, or all of the sensors within thesensor array 101 enables detection of whether thesensor array 101 is properly implanted within desirable tissue. Additionally, monitoring the sensor elements for proper hydration can be used as a trigger to enable at least one of calculation of a risk score, data recording, and/or data transmission. - Electrochemical impedance spectroscopy applied across any electrode pair within the
sensor array 101 can be used to measure or infer tissue impedance to determine tissue hydrations levels, or a fluid status within subcutaneous tissue of a subject being monitored. In some embodiments, fluid status of a subject is a risk metric contributing to the risk score of developing sepsis because fluid status provides context and a normalizing factor for other measurements, such as, and not limited to real time glucose, oxygen and lactate. Additionally, fluid status enables inference of capillary dysfunction which is an indicator of systemic inflammatory response syndrome (SIRS) or an ongoing progression of sepsis. Furthermore, absolute and trend information derived from tissue hydration levels enable adjustment or modifications to a risk score because goal directed fluid management can lose its effectiveness if the sign of fluid buildup (increasing tissue hydration levels or increasing rate of change of tissue hydration levels) are emerging. In still other embodiments, tissue hydration levels enable additional insight regarding perfusion of analytes within different types of tissues. For example, in various embodiments tissue hydration levels for asensor array 101 placed in muscle provides additional or less information than asensor array 101 that is placed in adipose tissue. - In some of these embodiments two of the three analyte sensor values are combined with data from any to all of the physical characteristic sensors to determine a risk score of developing sepsis. In other embodiments, all three of the analyte sensor values are used in conjunction with the data from any one to all of the physical characteristic sensors to determine a risk score of developing sepsis. The rationale for enabling risk score calculations based on less than all three analytes is to enable tailoring of the sensor array to a particular environment. For example, it may not be necessary to monitor glucose for a septic patient being monitored to determine efficacy of the therapy. Stated another way, for a patient already known to have sepsis, monitoring of glucose maybe optional because elevated glucose, as a metric within the system, is used to determine if an infection is progressing toward sepsis. Conversely, in an exemplary remote monitoring application where the objective is to identify early signs of the development of sepsis, the system may be highly tuned to monitor for elevations in glucose accompanied by decreases in tissue oxygen levels and optionally forgo any measurement of lactate.
- In many embodiments, the analyte sensors are intended to be placed in subcutaneous tissue where the plurality of working electrodes within the
sensor array 101 produce a corresponding plurality of signals. Placement within subcutaneous tissue enables a unique perspective for an oxygen sensor that is substantially different than common SpO2 oxygen measurements. Specifically, with embodiments of theanalyte sensors 101 a, oxygen within tissue is being measured rather than a measurement of SpO2 which is an estimation of arterial oxygen. When determining a risk score of developing sepsis it is advantageous to measure oxygen within tissue rather than estimated arterial oxygen because oxygen within tissue is a direct measurement of oxygen perfusion which is an early indicator of organ failure. - Supplementing the tissue oxygen signal are signals from the lactate and glucose sensors where each respective signal is proportional to an amount of analyte present in the subcutaneous tissue. In some embodiments, a two-electrode system is employed where each of the working electrodes electrochemically measure a particular analyte relative to a counter electrode. In other embodiments, a three-electrode system is employed where each of the working electrodes electrochemically measure a particular analyte relative to a counter and reference electrode.
- In some embodiments, each working electrode has a corresponding counter electrode while in other embodiments multiple working electrodes share a counter electrode. In still other embodiments, two working electrodes share a counter electrode while the third working electrode has a dedicated discrete counter electrode. Furthermore, the various embodiments of working electrodes and counter electrodes can be distributed among separate and discrete substrates. Typically, working electrodes and counter/reference electrodes are formed on a single substrate. However, an electrode design intended for use in the invention allows the complete physical separation of any of the working electrodes and any of the counter/reference electrodes. For example, as is shown in
FIGS. 1B-1 and 1B-2 working electrodes for analyte sensors can be formed onfirst sensor assembly 1001 while counter electrode are formed onsecond sensor assembly 1002. While the various electrodes may be separated on distinct substrates, in many embodiments thesensor array 101 having the plurality of working electrodes is inserted into the subcutaneous tissue via a single point of insertion. The use of a single insertion point minimizes both patient discomfort associated with insertion and insertion complexity. - The embodiments described above should not be construed as limiting. The sensor array should not be perceived as limited to subcutaneous placement for measurement of glucose, tissue oxygen and lactate. Other embodiments, for use in diagnosing or determining risk score for other conditions or diseases can employ various sensors to measure other combinations of analytes in different locations within the subject.
- Returning to
FIG. 1A , thesystem 100 additionally includes anelectronics module 102 that provides power for thesensor array 101 and enables bidirectional communication with other system components such as, but not limited to theexternal monitor 104,cloud computing systems 106 ormobile devices 128. Enabling theelectronics module 102 to perform such tasks are electronic module components such as, but not limited to acommunication module 108, aprocessor 110,memory 112, and apower supply 114 enclosed within an electronics module case. Theelectronics module 102 includes additional components, however, the specific components found inFIG. 1A warrant discussion regarding operation of thesystem 100. - In preferred embodiments the
power supply 114 provides power to theelectronics module 102 and also to thesensor array 101. Batteries, rechargeable or disposable, can be used for thepower supply 114. In order to minimize the likelihood of fluid ingress to the electronics module, it may be preferable to use inductive charging for embodiments using rechargeable batteries. Other embodiments use alternatives to batteries such as, but not limited to capacitors, supercapacitors, solar cells, fuel cells and the like. The specific examples provided for thepower supply 114 should not be construed as limiting. Rather, the examples provided should be viewed as examples of portable power supplies capable of supplying theelectronics module 102 and thesensor array 101 with power for the expected life of thesystem 100. - In some embodiments the
processor 110 is custom circuit such as but not limited to an application-specific integrated circuit (ASIC) or field programmable gate array (FPGA). In other embodiments theprocessor 110 is a more generic system on chip (SoC) or system in package (SiP). In instances where a SoC or SiP is utilized,communication module 108 andmemory 112 can be integrated within the SoC or SiP. In many embodiments the processor is in communication with thesensor array 101 receiving raw signal data from the plurality of working electrodes and other sensors. In some embodiments theprocessor 110 performs minimal manipulation of the raw data from the working electrodes. Examples of minimal manipulation include, but are not limited to filtering noise and compression. In these embodiments the data from the working electrodes is transmitted to a multitude of external devices via thecommunication module 108 where processing is completed to produce a risk score for sepsis. Alternatively, in other embodiments theprocessor 110 executes stored instructions to process the sensor data before transmitting processed data that may include a risk score for sepsis to any external devices via thecommunications module 108. - In many embodiments the
communications module 108 is based on personal area network technology commonly referred to as Bluetooth low energy (BLE) or Bluetooth Smart. In other embodiments, a customized or semi-custom communication standard is utilized. However, one common trait for anycommunication module 108 is the ability to securely send and receive data between at least a third party device and theelectronics communication module 102. The ability to securely transmit either raw or processed data using thecommunications module 102 enables flexibility that allows thesystem 100 to be adaptable from a mobile monitor to being an integral component within a hospital ward. - In one embodiment data from the
sensor array 101 is sent via thecommunications module 108 to acloud computing system 106, also commonly referred to as “the cloud”. In still other embodiments data from thesensor array 101 is transmitted via thecommunications module 108 to anexternal monitor 104. Clinical settings such as a hospital ward where multiple monitors display a plurality of condition being monitored for a patient could be ideal settings for embodiments where theelectronics module 102 transmits to anexternal monitor 104 or thecloud 106. For example, with the appropriate infrastructure data from thesensor array 101 can be transmitted in real-time to an electronic medical record stored in thecloud 106. Alternatively, in some embodiments data can be transmitted from theexternal monitor 104 to thecloud 106 where it is stored as part of an electronic medical record. - In still other embodiments, the
electronics module 102 transmits data from thesensor array 101 to amobile device 128 such as, but not limited to a smartphone, a smartwatch, a portable fitness monitor, a tablet, a notebook computer, an ultrabook computer, or an aftermarket or integrated infotainment center for a vehicle. The examples of amobile device 128 are not intended to be construed as limiting. Rather, the examples are intended to provide guidance regarding the types of devices that can receive and/or transmit data to theelectronics module 102. Accordingly, devices that can be viewed as similar to those listed should be considered contemplated by the current disclosure. In embodiments where themobile device 128 includes a connection to the internet, themobile device 128 can send data to thecloud 106 where the data can be archived, shared with other devices, be further processed or become data to enable machine learning. Utilizing the data to enable machine learning further enables data-driven improvements such as development of algorithms that are patient specific or algorithms that are applied universally across all patients. For example, depending on how much information is provided with the data provided for machine learning, patient specific algorithms can include, but are not limited to factors such as age, race, weight, and pre-existing conditions. Similarly, regardless of patient specific information, all data processed via machine learning can be utilized to improve algorithms with the goal being improved outcomes for all patients. - Even with embodiments where additional processing is handled on either an
external monitor 104 or thecloud 106,memory 112 can be used to store data from thesensor array 101 on theelectronics module 102. Using thememory 112 to store data from thesensor array 101 can ensure sensor data is not lost if there are connectivity interruptions between theelectronics module 102 and theexternal monitor 104, thecloud 106, or amobile device 128. Thememory 112 can further be used to store program instructions for the processor, or to store values for variables used by theprocessor 110 to output a risk factor for sepsis. - In many embodiments the
electronics module 102 is removably coupled with thesensor array 101. With these embodiments, theelectronics module 102 is capable of being reused after thesensor array 101 is deemed consumed or depleted. In other embodiments, a permanent coupling is achieved after an initial coupling between theelectronic module 102 and thesensor array 101. In these embodiments, theelectronics module 102 is considered disposable and is intended to be discarded after thesensor array 101 is deemed consumed. Alternatively, to reduce environmental impact, select portions of the electronics module, such as, but not limited to thepower supply 114 andcommunications module 108 are recyclable. In many embodiments, initially coupling theelectronics module 102 to thesensor array 101 provides power to the electrodes and initiates the program instructions stored in either theprocessor 110 or thememory 112. - In many of these embodiments, the electronics module includes a feedback device 113. The feedback device 113 provides feedback regarding the status of the combined
electronics module 102 andsensor array 101. For example, in some embodiments the feedback device 113 is a single or a plurality of multi colored LED that blinks a first color and/or first pattern when the system is functioning with design parameters and a second color and/or second pattern if there is an error within the system. In other embodiments, the LED is a single color that uses different frequency of blinks to convey status of the system. In still other embodiments, the feedback module includes a vibration device similar those used in mobile phones to convey status of the system. In still other embodiments, a piezo or other audible sound emitting device is used as the feedback device 113. - The
external monitor 104 may include some components not found in theelectronics module 102, such as a graphic user interface (GUI) 122 and adisplay 124. Other components of theexternal monitor 104, such as acommunication module 116, aprocessor 118, a memory and apower supply 126 may seem duplicative of components in theelectronics module 102, but may have different or improved capabilities or functionality. For example, while thepower supply 114 of theelectronics module 102 may be a battery, thepower supply 126 for theexternal monitor 104 may include an AC power supply that is supplemented with a rechargeable battery to enable theexternal monitor 104 to operate seamlessly between being plugged into a wall socket and being moved throughout a hospital until it can be eventually be plugged back into a wall socket. - For purposes of this invention, the
GUI 122 further includes human interface devices that enable interaction with theGUI 122 such as but not limited to virtual or physical keyboards, touchscreens, joysticks, control pads and the like. Accordingly, use of theGUI 122 in conjunction with thedisplay 124 enables user input to thesystem 100 and further allows selection or customization of what is shown on thedisplay 124. TheGUI 122 in conjunction with thecommunication module 116 and thecommunication module 108 further enables settings on theelectronics module 102 to be manipulated or adjusted to optimize output from thesystem 100. Similarly, theGUI 122 enables user input to theprocessor 118 or thememory 120 to enable input and adjust settings that are applied to data from thesensor array 101 to determine a risk factor for sepsis. - The system further optionally includes a
mobile device 128 having a user interface, such as, but not limited to a smartphone, a mobile phone, a smartwatch, a laptop, an ultrabook, a tablet computing device, a pager, and the like. Themobile device 128 is configured to receive data from theelectronics module 102 via at least one of thecloud 106, theexternal monitor 104, or theelectronics module 102 itself. In many embodiments themobile device 128 is in bidirectional communication with theelectronics module 102 which enables input via the user interface of themobile device 128 to be transmitted to theelectronic module 102. This enables a user of themobile device 128 to manipulate, configure, or program settings on theelectronics module 102. In some embodiments, bidirectional communications enables processing of data from thesensor array 101 on themobile device 128. Additionally, in embodiments where themobile device 128 includes a display, real time data and trends derived from the data is shown on themobile device 128. In embodiments where themobile device 128 includes at least one of an audible, tactile and visual alarm, themobile device 128 can be used to update users of themobile device 128 of the status of a patient wearing thesensor array 101. The status of the user includes, but is not limited to whether thesystem 100 is functioning properly, faults within thesystem 100, or real time measurements from thesensor array 101. - Another optional component within the
system 100 is thecloud 106. Generally, thecloud 106 is considered some type of cloud computing which can be generalized as internet based computing that provides on demand shared computing processing resources and data to computer and other internet connected devices. In some embodiments thecloud 106 receives data from theelectronics module 102 directly. In other embodiments data from the electronics module is transmitted to themobile device 128 before being transmitted to thecloud 106. In still other embodiments, thecloud 106 receives data from theelectronics module 102 via theexternal monitor 104. In still other embodiments, various permutations of communications initiated by the electronics module and transmitted between theexternal monitor 104 and themobile device 128 results in data being transmitted to thecloud 106. - Data received by the
cloud 106 may have already been processed by an intermediary device or can be processed on thecloud 106 and transmitted back to the intermediary device. In some embodiments, thecloud 106 contains electronic medical records and data from thesensor array 101 is automatically uploaded to the electronic medical records. With real time data being uploaded to the cloud, it becomes possible to apply machine learning which can further enable automatic or semi-automatic adjustments to theelectronics module 102. Automatic updating would result in changes to the programming of the electronics module without human intervention whereas semi-automatic updating would require someone to confirm changes to the programming of theelectronics module 102. In one example, thecloud 106 enables examination of medical history such as pre-existing conditions and family history and machine learning can suggest or set customized thresholds and sensor sampling rates based on previous data from patients with similar conditions and data - The previously discussed components or elements within the
system 100 are intended to be exemplary rather than limiting. As the system is intended to be flexible components are able to be added and removed based on immediate needs. This includes enabling or disabling system components within one environment while enabling or disabling the same system components at a later point. For example, a facility utilizing the system for triage may not implement or enable communications tomobile device 128 while enabling communication with thecloud 106. However, once a patient is moved from triage to a monitoring or remote monitoring environment, communication with a mobile device may be enabled. Similarly, a hospice may choose to not enable communication with thecloud 106. -
FIG. 2A is an exemplary flowchart illustrating operations performed by various components of thesystem 100 to determine a risk score for sepsis, in accordance with embodiments of the invention. The flowchart begins withstart operation 200 followed byoperation 202 that initiates the sensor array. In many embodiments,operation 202 occurs when electrical contact is made between the power supply in the electronics module and the working electrodes within the sensor array. Inoperation 204, data is received from the sensor array. In some embodiments data is received at the processor associated with the electronics module. Alternatively, in other embodiments the data can be viewed as being received from the electronics module at an external monitor, a mobile device or the cloud. -
Operation 206 takes the received data and stores it in a memory. The memory can be associated with the electronics module, an external monitor, the cloud or the mobile device. Withoperation 208 data from the sensor array is evaluated using the processor. Similar to storing the data, evaluation of the data can occur on the electronics module or any number of devices in communication with the electronics module such as the external monitor, the cloud or a mobile device. The risk score determined byoperation 208 is output tooperation 209 that displays the risk score. The risk score fromoperation 208 is also passed tooperation 210 that determines if the risk score exceeds an alarm threshold value. If a risk score threshold value is exceeded,operation 212 outputs an alarm such as an audible, visual, tactile or combination thereof. Embodiments having the requisite infrastructure can enable alarms or alerting at remote locations such as, but not limited to external monitors, mobile devices and other cloud connected devices. If the risk score is below an alarm threshold, the flowchart returns tooperation 204 where new data from the sensor array is received. -
FIG. 2B is an alternative embodiment ofFIG. 2A that executesoperation 214 afteroperation 210.Operation 214 determines if the evaluated data is trending toward an alarm threshold. If the data is trending toward an alarm condition,operation 216 increases the data sampling rate so data is received atoperation 204 at a higher rate. If the data is not trending toward an alarm condition the flowchart returns tooperation 204 where additional data is received from the sensor array. One advantage of increasing the sampling rate is to achieve improved resolution of the rate of change of an analyte. Selectively changing the sampling rate based on real time conditions, or dynamic sampling, can be implemented in various ways because the risk score is determined from multiple analytes. In one embodiment each working electrode has a dynamic sample rate that is completely independent from the sampling rate of the other working electrodes. In another embodiment, the sample rate of all of the working electrodes is dynamically tied the output of a single working electrode. However, with embodiments that increase the sample rate of all the electrodes, it may not be necessary to utilize all of the data when determining a risk score. Accordingly, in some embodiments, even with increased sampling rates, particular metrics may be determined on data gathered at rates other than the sample rate. For example, if a rate of change of oxygen results in increased sampling rates for all analytes, the calculations for the rate of change of lactate may not be based on the increased sampling rate. However, if lactate levels or the rate of change of lactate eventually indicate that increased sampling rates would be beneficial, the rate of change of lactate calculations can be based on the increased sampling rate. Alternatively, the overall sampling rate of all the electrodes can be further increased beyond the original increase for oxygen. Thus, the rate of change for lactate can push for higher sampling rates and the oxygen calculations can continue to be made at the original increased frequency. Thus, while an overall sampling rate may be implemented across all of the working electrodes, the calculations for the respective analytes may be dynamically determined on a preferred sample rate for each analyte. -
FIG. 3A-1 is an exemplary hybrid flowchart and block diagram illustrating operations and elements used to performoperation 208 that evaluates risk metrics provided by thesensor array 101 andother inputs 308 to determine a risk score, in accordance with embodiments of the invention. Thesensor array 101 includesanalyte sensors 101 a andphysical sensors 101 b. In many embodimentsphysical sensors 101 b include, but are not limited to sensors like accelerometers and thermometers that respectively generate risk metrics such as movement and temperature. Theanalyte sensors 101 a include, but are not limited to sensors that measure risk metrics like glucose, oxygen, and lactate in real-time within subcutaneous tissue. - In preferred embodiments, a single point of entry is used to insert the
analyte sensors 101 a within subcutaneous tissue. Depending on the types of physical sensors included within thesensor array 101, some physical sensors may be implanted within subcutaneous tissue while other physical sensors remain outside of the subject but still incorporated within the electronics module. In these embodiments, the analyte sensors are implanted with via a single point of entry but some or all of the physical sensors are coupled with the sensor assembly concomitant with attachment of the electronics module. Despite using a single point of entry, in some embodiments theanalyte sensors 101 a are distributed among multiple separate substrates. However, in other embodiments, theanalyte sensors 101 a are disposed, or located, on a single substrate. Irrespective of relative placement of theanalyte sensors 101 a,operation 204 collects data from theanalyte sensors 101 a and thephysical sensors 101 b and in accordance withoperation 206 ofFIGS. 2A and 2B , stores the data into a memory. The physical location thememory 206 may vary between being located within theelectronics module 102, on the external monitor 103 thecloud 106 or themobile device 116. Regardless of where the data from thesensor array 101 is stored,operation 208 evaluates the data to determine a risk score of developing sepsis. - As shown in
FIG. 3A-1 ,operation 208 is dependent on data collected from thesensor array 101.Operation 208 can be supplemented withother inputs 308 to improve or enhance determination of a risk score, butother inputs 308 are not required to determine a risk score. It is the real-time measurements of glucose, lactate, and tissue oxygen risk metrics that enable determination of a risk score for developing sepsis across multiple environments. For purposes of this disclosure “real-time” or “substantially real-time” should be construed to mean the actual time during which something takes place, or within milliseconds so the measurement is available virtually immediately. - Within operation 208 a
metrics processing module 300 receives sensor data that was previously stored in memory byoperation 206. Exemplary inputs to themetrics processing module 300 include primary inputs, or primary data, that are defined as signal data received from the sensors array for measured risk metrics such as glucose, lactate, tissue oxygen, tissue hydration, temperature and the like. In many embodiments themetrics processing module 300 allows the primary inputs to be passed through tooperation 306. In other embodiments, themetrics processing module 300 also calculates secondary inputs which are defined as inputs or metrics that are calculated based on primary inputs before being input tooperation 306. - Examples of secondary inputs include, but are not limited to ratios between primary inputs, rates of change of primary inputs, and rates of changes of ratios between primary inputs. Inclusion of secondary inputs can improve or enhance the determination of the risk score because specific changes in specific ratios of measured analytes, or primary inputs, can be an indicator of dysregulation, or the development of sepsis. An example of a secondary input that can be valuable in determining a risk score for sepsis is the ratio of glucose to tissue oxygen. This ratio can contribute to the risk score because an increase in glucose relative to tissue oxygen can be indicative of hypoxia, a precursor to sepsis. Another secondary input, the ratio of lactate to tissue oxygen, is indicative of hypoxia, when there is an increase in lactate relative to tissue oxygen. Still another secondary input that is an exemplary precursor to sepsis is the ratio of glucose to lactate. A measurable increase in glucose concentration relative to lactate can be suggestive of anaerobic glycolysis, another precursor to sepsis. Accordingly,
operation 300 can be summarized as receiving primary inputs (analyte sensor data and physical sensor data) and outputting tooperation 306 both primary inputs and secondary inputs (metrics calculated based on primary inputs). - Optionally supplementing
operation 306 areother inputs 308 that are based or derived from external data obtained from outside the sensor array, and this can include additional risk metrics along with a subset ofrelative weights 310.Relative weights 310 are used to modify primary, secondary and other inputs and will be discussed in moredetail regarding operation 310′.Other inputs 308 are defined as risk metrics that impact a risk score that are not measured by thesensor array 101, and may even be used to determine a risk score without any input at all from the sensor array. For clarity,other inputs 308 may include discrete measurements of a risk metric (e.g. a one-off lab test), periodic/episodic risk metrics (e.g. periodic test results, periodic discrete analyte(s) measurement(s) with finger pricks, etc.) or continuous real-time measurements from supplemental medical monitors (such as heart rate, blood pressure, or even peripheral oxygen saturation rates using non-invasive pulse oximetry as an approximation of the more accurate invasive measurement of tissue oxygen via the sensor array 101). Examples ofother inputs 308 include, but are not limited to data or metrics commonly available from lab/clinical tests, or continuously collected through readily available hospital monitoring equipment. If enabled, some embodiments receiveother inputs 308 from electronic medical records stored incloud 106. Alternatively, a GUI associated with a monitor or mobile device can be used to supplyother inputs 308. For example,other inputs 308 include risk metrics such as, but not limited to heart rate, respiratory rate, urine volume, blood pressure, cognitive/neurological assessment scores, and age. Forother inputs 308 that are based on measured values like the sample above, some embodiments ofother inputs 308 enable calculations of rates of change and ratios between various other inputs. For example, rates of change of heart rate and rates of change of blood pressure.Other inputs 308 can further include any disease states of a subject along with any associated comorbidity risk factors. Inclusion of disease states or particular chronic illnesses further enhances the ability to determine a meaningful risk score of developing sepsis, and the following chronic disease states listed in decreasing order of risk, can contribute to an increased risk of developing sepsis: AIDS, liver failure, cancer, and generally immune compromised patients. -
Operation 306 receives risk metrics in the form of primary and secondary inputs from themetrics processing module 300 along with anyother inputs 308 and transforms and normalizes the various inputs into risk values that are functions of the original risk metrics. In preferred embodiments, the risk values are a number between zero and one where one is a high risk for developing sepsis and zero is a low risk for developing sepsis. When transforming and normalizing primary and secondary inputs, one embodiment looks for deviations from baselines to determine a risk value. In another embodiment, the risk value is determined by comparing measured primary and secondary inputs to threshold values. The transformation and normalization performed byoperation 306 converts individual risk metrics to unitless risk values that enables comparison and relative weighting to be applied across the risk values. - The output of
operation 306, the risk values between zero and one, are input intooperation 302 that stores the risk values into a risk index. The risk index is defined as a compendium of all of the transformed and normalized risk values. Storage of the risk values within the risk index enables any or all of the individual risk values to be displayed inoperation 312. Display of individual risk values can help provide context to a health care provider regarding particular risk metrics within the risk score. For example, inclusion of the risk index enablesoperation 312 to display lactate trends for a subject which can further provide context and insight into the behavior of the risk score. Without storage of the risk values within the risk index, a healthcare provider may only be able to see the end result risk score without context of the risk values. This could lead a healthcare provider to speculate the cause of the risk score behavior rather than simply being able to see changes in the risk values over time on a display. - A
next operation 303 determines if relative weights are applied to the risk values within the risk index. If relative weights are not applied,operation 304 determines the risk score by taking the sum of the risk values. If relative weights are applied,operation 310′ appliesrelative weights 310 to appropriate risk values beforeoperation 304 then calculates a weighted average risk score. - The following are examples of reasons it may be preferred to use other inputs 308 (such as information on a chronic illness or disease state) as
relative weights 310 that modify the calculation of a risk score. When a subject being monitored is diabetic there may be greater variations in glucose measurements. Diabetes can further affect lactate measurements as both ketoacidosis and metformin consumption may lead to increased lactate in a subject already predisposed to generally higher lactate levels. Other examples of chronic conditions that can affect lactate levels include, but are not limited to metastatic cancer, leukemia/lymphoma, or the presence of solid tumors. Accordingly, associating a relative weight to specific risk metrics affected by particular pre-existing or chronic condition such as diabetes, cancer, leukemia or other immune-compromised condition enables emphasis or de-emphasis of single, multiple, or all primary, secondary and other inputs. -
FIG. 6 is a table of exemplary relative weights that can be applied to various risk metrics when a system is applied in a triage environment for a non-diabetic subject and a diabetic subject. As shown inFIG. 6 , the relative weights of zero ensures that the greater variations in glucose measurements from a diabetic subject do not influence determination of the risk score in triage mode. However, the autoimmune disorder relative weight of three may result in an overall more conservative determination of a risk score.FIG. 6 is intended to be an exemplary illustration of how relative weights can be used to influence different primary and secondary metrics used to determine the risk score of developing sepsis. Other chronic disease states may require different relative weights based on how the disease state impacts a particular metric. - Other
relative weights 310 can also be customized or tailored to be specific to a particular hospital, health system, physician or patient need. For example, therelative weights 310 may be customized to better fit a particular hospital workflow such as where a hospital intensive care unit already utilizes sepsis scorecards that assign different relative weights to various lab/clinical tests. In these embodiments, therelative weights 310 for the system can be customized to follow similar, if not exact matches to the existing sepsis scorecards. Similarly, the relative weights can be adjusted based on the whether the patient is in a triage, patient monitoring or remote monitoring environment.FIG. 7 includes a table of exemplary relative weighting coefficients that can be applied to various risk metrics based on the subject's environment. - The examples discussed above are intended to be exemplary and should not be construed as limiting, especially regarding the analytes and combinations thereof. Other embodiments capable of measuring different, alternate or additional analytes or risk metrics to derive a risk score of developing sepsis or other disease or physical condition should be considered within the scope of this disclosure.
- The output of
operation 304, the risk score, is used as input intooperation 210 that determines if the risk score is greater than an alarm threshold and the flowchart is completed as shown inFIGS. 2A and 2B . Note,operation 208 is capable of providing output to a display on a hospital monitor, mobile device, or other screen based on output from eitheroperation 302 of the risk values within the risk index and/or the risk score fromoperation 304. Accordingly,operation 312 is intended to display visual representation of real-time and/or historical data such as the risk score or individual risk values from within the risk index. For example, in some embodiments, particularly those in the patient monitoring environment, real time charts of the measured analyte data are shown on adisplay 312 in addition to a final risk score. In other embodiments, such as those in the remote monitoring environment, a simplified display showing the resulting risk index is displayed on a mobile device such as a smartphone. In embodiments where data from the remote monitoring device is concurrently being reviewed by an attending physician, additional data such as real time charts from the chemical sensors may be displayed for the physician. The ability to display individual risk values can provide meaningful insight to physicians and medical staff regarding changes, or lack of changes to the risk score. -
FIG. 3A-2 is an exemplary hybrid flowchart and block diagram further including the application of conditional logic or conditional weights, in accordance with embodiments of the invention. The ability to include conditional logic allows use of prior outputs as input thereby enabling more complex methods to determine a risk score. Differentiation betweenFIG. 3A-1 andFIG. 3A-2 manifest whenoperation 303 determines that relative weighting is applied to the risk values. InFIG. 3A-2 , if the risk values are augmented by relative weighting, therelative weights 310 are carried intooperation 350 that determines if a conditions, or conditions, have been satisfied. The condition, or conditions are drawn from anything measured by, or input into the system or stored in the system memory. For example, conditions may be applied to primary or secondary inputs, risk values or a previously determined risk score. Failure to meet a condition can results in adjustments being made to a single relative weight for the single risk value, adjustments to the relative weights for other risk values, or adjustment to the relative weights of all the risk values. - In an exemplary embodiment there are conditions for risk values associated with oxygen, impedance, rate of change of temperature. In this example the condition for oxygen is not met resulting in an adjustment being made to a relative weight. The relative weight being adjusted can be for oxygen, impedance, rate of change of temperature or any other primary, secondary input, risk value or even previously determined risk score. Additionally embodiments include conditions that are chained, like a conditional tree with branches for decisions points. For example, if oxygen and glucose risk values hit independent target thresholds, make an adjustment to the relative weighting factor for lactate. The particular conditions and changes to relative weights discussed above are intended to be exemplary rather than comprehensive. Other conditions, or combinations of conditions can drive changes to the relative weights to further improve the determination of the risk score.
- If the condition, or conditions of
operation 350, are notsatisfied operation 360 adjusts therelative weights 310 before passing the adjusted relative weights tooperation 310″ that applies the adjusted relative weights to the risk values. If the condition or conditions ofoperation 350 are satisfied,operation 310″ applies the unadjustedrelative weights 310 to the risk values. In a later operation, 304, the risk score is determined based on risk values untouched by relative weights fromoperation 303, or risk values that have been adjusted with either adjusted relative weights or original relative weights. -
FIG. 3B is a hybrid flowchart and block diagram illustrating exemplary operations within themetrics processing module 300, in accordance with embodiments of the invention. Operation 300-2 starts processing primary data that enters themetrics processing module 300. Subsequent operation 300-4 applies noise detection and operation 300-6 applies smoothing filters, to the primary data within themetrics processing module 300. The output from operation 300-6 is passed to operation 300-8 that uses smoothed primary data to determine rate estimations or the first type of secondary input or secondary data. Subsequently, rate estimations from operation 300-8 are used by operation 300-10 to determine predictive values. The output of operations 300-6, 300-8 and 300-10 are also provided to operation 300-12 that performs a first signal transformation. In some embodiments the signal transformation includes, but is not limited to calibration or utilization of look-up tables to transform or translate the respective signals into relevant units. For example, when primary input such as glucose data entersoperation 300 it may be in the form of measured current from the working electrode of the multianalyte sensor. After passing through operation 300-6 and upon completion of operation 300-12, the original current measurement is transformed or translated into an instantaneous concentration of glucose in units such as millimole of glucose. When utilized within the scope of a triage scenario, instantaneous measurements of primary inputs glucose, lactate, and tissue oxygen help determine if conditions within the subject are indicative of sepsis when the measurements deviate significantly from normal ranges. - The
metrics processing module 300 is also capable of looking at measurements over windows of time, or the rates of change of primary inputs, and provide additional insight or even a predictive capability for detecting conditions that can lead to the onset of sepsis. For example, rates of change of data measured by the sensor array and passed through both operations 300-8 and 300-12 result in the rates of change of lactate, glucose and tissue oxygen. Additionally, predicted measurement of glucose, lactate and tissue oxygen are also output if data passes through operations 300-10 and 300-12. - An example of using predictive measurements to determine a risk score is found when examining stress-induced hyperglycemia, a known marker for sepsis. Accordingly, the ability to detect or predict the onset of high blood glucose levels is extremely desirable when developing the risk score of developing sepsis. To obtain the prediction a projection in time can be achieved by calculating a trend from recent glucose concentrations values, or in one embodiment, the change of glucose measurement over time, or more simply, the glucose derivative. A common method to estimate the glucose derivative is to apply convolution (i.e. Savitzky-Golay filtering algorithm) to the data. In other embodiments, future glucose measurement are estimated using more advanced algorithms that additionally use the noise content of the signal as an input to compute the prediction (i.e. a Kalman filter).
- Regardless of the specific filter applied to the data to determine a predicted value, the predicted value may be included as a risk metric when determining the risk score for the onset of sepsis. However, due to relative uncertainty related to predictions and projections into the future, any predicted value can be adjusted appropriately via
relative weight 310 that can be applied to adjust risk scores. Accordingly, for many embodiments, the relative weight for predicted glucose may be lower than the relative weight for instantaneous glucose measurements. However, in still other embodiments, the relative weights for the various data points and rates of change may be tuned to optimize for either certainty or predictive capability. - Another indicator or signal of the onset of sepsis is lack of glycemic control. With some embodiments of the invention a time-in-range calculation or a time-out-of-range metric, normalized to a percentage of the evaluated window time is used as a metric to reflect the ability of the patient to manage glucose concentrations. Glycemic control, unlike the previously discussed trend and predictive data, is a trailing indicator and requires significantly more time (i.e. data points) before a reasonable calculation can be made. For example, the glycemic control metric may require hours, or even multiple days' worth of data points instead of the minutes of data required for predictive metrics. Accordingly, effective use of a glycemic control metric may be found when the system is utilized in an outpatient setting to monitor trends over extended periods of time.
- As with glucose concentrations, elevated lactate concentrations are a marker for sepsis and the onset of sepsis. Conversely, decreasing oxygen saturation is also associated with an increased risk of sepsis. Following the same methods described above for glucose, trending data for lactate concentrations may similarly be calculated to support acute prediction/diagnosis of sepsis. Likewise, calculation of oxygen saturation rate of change should follow the same algorithms used for glucose and lactate. However, unlike glucose, naturally decreasing lactate concentration, or clearance of lactate, by the body is a signal of decreasing risk of sepsis. Thus, a negative lactate rate of change would represent one of the few negative risk values. Similarly, elevated lactate concentrations coinciding with regular or faster than regular lactate clearance may not be considered cause for alarm because the subject continues to clear lactate from the body at a regular or above regular rate.
-
FIG. 4A is an exemplary chart illustrating how temperature risk metrics are converted to normalized temperature risk values, in accordance with embodiments of the invention. With infections, immune response typically results in an initial increase in body temperature. As dysregulation occurs associated with organ failure, hypothermia becomes a possibility. However, in either situation, hypothermia or hyperthermia, deviation from normal body temperature is associated with increased risk of mortality. As shown inFIG. 4A , normothermia is centered around 37 Celsius and is associated with a very low risk value. However, as temperature deviates toward either hypothermia or hyperthermia, the temperature risk value begins to increase toward a value of one. -
FIG. 4B is an exemplary chart illustrating conversion of lactate sensor readings to normalized lactate risk values, in accordance with embodiments of the invention. Normal plasma lactate concentration is 0.5 to 1.5 milliequivalents per liter. Lactic acidosis is generally defined as a plasma lactate concentration greater than 4 milliequivalents per liter, even in the absence of overt academia. In sepsis, the inability of the body to support lactic acid clearance results in increased levels of lactate, as high as 20 milliequivalents per liter. In light of the previously disclosed risks associated with lactate concentrations, the lactate risk value increases sharply upon exceeding 2.0 milliequivalents per liter and reaching a maximum of 1 after the lactate concentration approaches limits outside of lactic acidosis. However, because acute increases (followed by gradual decreases) in lactate concentration can occur as a result of physical exertion such as exercise, for remote monitoring embodiments the maximum relative weighting factor can be limited to 0.5 rather than 1 for lactate concentrations between four and six milliequivalents per liter. In still further embodiments, the change of lactate risk value based on exercise occurs automatically when a physical sensor measuring movement detects continuous motion associated with exercise. Other modifications to the lactate risk value chart can be made based on other inputs such as, but not limited to chronic disease states and certain types of medication. -
FIGS. 4C and 4D are exemplary charts illustrating how glucose risk values can change in accordance with embodiments of the invention. The American Diabetes Association defines tight glucose control is achieved between the range of 3.9-7.2 millimol/L (70-130 mg/dL). Deviations outside of this range are correlated with long-term health effects typically associated with diabetes mellitus. Similarly, in the intensive care unit setting both hypoglycemia and hyperglycemia are associated with increased mortality with hypoglycemia carrying a greater risk of death. In the case of sepsis, an argument can be made to exclusively track hyperglycemia because sepsis is correlated with elevated glucose levels.FIG. 4C is an exemplary chart of glucose risk values that places a greater risk of developing sepsis on hyperglycemia. - In embodiments that take into consideration mortality rates rather than strictly sepsis detection and diagnosis, the risk index can further include consideration of hypoglycemia. Consideration of hypoglycemia can result in a glucose risk value chart similar to that found in
FIG. 4D where the glucose risk value approaches or is equal to zero around the tight glucose control range of 70-130 mg/dL. In still further embodiments, a log-normalized approach can be considered to generate a more evenly matched relative weights between hypoglycemia and hyperglycemia.FIGS. 4C and 4D further illustrate how conversion and normalization of risk metrics to risk values are customizable based on hospital protocols, physician preferences, or other considerations. -
FIG. 4E is an exemplary chart of risk values associated with a secondary input, specifically, a rate of change of lactate, in accordance with embodiments of the invention. As previously discussed, lactate trending data may be determined to support acute diagnosis or prediction of sepsis. Also previously discussed is decreasing lactate concentration being a signal of decreasing risk of sepsis and corresponding negative risk value. -
FIG. 5 is an exemplary flowchart illustrating integration of the system within a therapy management system to enable a feedback mode in accordance with embodiments of the invention. Feedback mode is intended to monitor the effects of any treatment protocol and provide real-time, actionable information to external control algorithms whose aim is to optimize the management of therapy delivery to subjects with sepsis or a high risk of developing sepsis. This is accomplished by modifying therapy based on system output achieving targets and/or setpoints for specific risk metrics based on a specific clinical protocol. For example, if the clinical protocol is early goal directed therapy, feedback mode enables automatic or semi-automatic adjustments to the therapy based on the output of the system. - Operation 500 initiates feedback mode assuming the subject is already being monitored by the system and a decision has been made to initiate a therapy which is executed by operation 502. Various forms of therapy for sepsis include, but are not limited to fluid resuscitation or infusion of dobutamine. In a
subsequent operation 504 data from the system, such as the risk score, along with real-time sensor values and rates of change in sensor values is gathered and used as input for the next operation. Later,operation 506 determines error in the input versus the targets and setpoints associated with the therapy.Operation 508 inputs the error fromoperation 506 into a controller that in operation 510 determines if changes to the therapy is needed. If augmentation to the therapy is recommended, in semi-automatic mode the system can notify a healthcare provided of suggested changes. In automatic mode, the system is enabled to make changes to therapy parameters such as infusion rates and the like. If the therapy protocol is within the targets or setpoints so no changes are recommended, operation 510 the flowchart returns tooperation 504. The therapy management system described above incorporates a feedback loop. Other embodiments of the therapy management system can be further enhanced or improved with the addition of adaptive control. For example, in an embodiment employing adaptive control, if elevated lactate levels coincide with an increasing lactate clearance rate above a specified threshold, the risk score can be determined without taking into account the elevated lactate levels. - As previously discussed, the system is intended to be used in a variety of modes such as, but not limited to triage, monitoring, and remote monitoring each optionally supplemented by a feedback mode. Triage mode is intended to rapidly determine if a patient is afflicted with sepsis. The monitoring mode is intended to either monitor progress of a septic patient or provide notification if a patient is potentially developing sepsis. The remote monitor mode is intended to leverage mobile technology and cloud based communications to provide early notification of the potential development of sepsis in high-risk patients away from traditional medical or care facilities. The particular embodiments discussed above are exemplary embodiments of the system and should not be construed as the explicit limits of the system.
- Other embodiments of the invention include separately or together, both detection and disease management based on continuous real time monitoring of multiple analytes indicative of disease states or medical conditions. For example, the system is adaptable to monitor the effectiveness of treatments such as, but not limited to chemotherapy. As many types of cancer are known to produce hyper metabolic activity within close proximity of a tumor, real time monitoring of metabolic activity near the tumor can provide insight of the efficacy of treatment. Similarly, the system is further adaptable to provide real time measurements and monitoring of analytes that are indicative of metabolic conditions and disease states associated therewith.
- In addition to monitoring efficacy of cancer therapy and treatments, embodiments of the invention can also be used to monitor for conditions indicative of cancer in light of the following pathophysiological for some types of cancer. High energy metabolites such as ketones and lactate are associated with accelerated tumor growth and tumor metastases. Furthermore, increases in anabolic tumor growth rates are associated with upregulated mitochondrial metabolism which often are the byproduct of increases in circulating oxygen. Unique to behavior of cancer cells is the so called Warburg effect which describes the increased conversion to glucose to lactate even in the presence of normal to high levels of circulating oxygen. The energetically inefficient nature of the Warburg effect drives increases in glucose uptake through signaling pathways that ultimately leads to increases in insulin resistance and a concomitant increase in circulating glucose. The complex interplay amongst metabolic pathways associated with cancer cells suggest a continuous monitor capable of measuring ketones, oxygen, glucose, and lactate can be used to monitor those at risk for cancer, those who are being treated for cancer, and those who are at risk for cancer recurrence.
- The continuous measurement of metabolites, their rates of change, and their relative concentrations can be analyzed through algorithms that serve to simulate or model the pathophysiological processes associated with tumor or cancer cell growth in order to identify individuals whose cancer risks have markedly increased and to then alert members of the care team through wired or wireless communication methods who can then initiate the appropriate intervention. A cancer monitoring system such as the one described above can also be used to monitor the effectiveness of a range of treatments and may in fact be used to enable more effective continuous treatment as opposed to the episodic or periodic protocols that tend to be reactive and as a result less effective in regards to treatment efficacy.
- In embodiments not associated with metabolic conditions, the system is configurable to measure reactive oxide molecules such as, but not limited to nitric oxide and superoxide. As part of the body's inflammation response reactive oxide molecules are often overexpressed. Overexpression of reactive oxide molecules can cause the disruption of processes in the mitochondria and may have a role in mitochondrion dysfunction. Monitoring or detecting reactive oxide molecules and superoxide in relation to inflammation can be valuable within a hospital because of the strong indication for infection, regardless of patient profile.
- While the description above refers to particular embodiments of the invention, it will be understood that many modifications may be made without departing from the spirit thereof. The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (21)
1.-20. (canceled)
21. A system to enable risk assessment of the onset of sepsis, comprising:
a sensor array placed within subcutaneous tissue via a single point of entry to continuously monitor analytes that are indicators of the onset of sepsis, the sensor array having a plurality of working electrodes, each of the plurality of working electrodes configured to measure a different analyte in real-time;
an electronics module having a processor, a memory and a bi-directional communications module, the electronic module coupling with the sensor array such that the processor calculates a risk score for the onset of sepsis based on characteristics of the different analytes, the risk score being transmitted and produced on a display;
wherein the sensor array includes working electrodes configured to measure lactate and tissue oxygen.
22. The system of claim 21 , wherein the sensor array further includes a working electrode configured to measure a third analyte in real-time.
23. The system of claim 22 , wherein the third analyte is glucose.
24. The system of claim 23 , wherein calculating the risk score includes calculating a ratio of the concentrations of any two of analytes being measured in real-time.
25. A system to enable risk assessment of the onset of sepsis, comprising:
a sensor array placed within subcutaneous tissue via a single point of entry to continuously monitor analytes that are indicators of the onset of sepsis, the sensor array having a plurality of working electrodes, the plurality of working electrodes configured to measure different analytes in real-time;
an electronics module having a processor, a memory and a bi-directional communications module, the electronic module coupling with the sensor array such that the processor calculates a risk score for the onset of sepsis based on characteristics of the different analytes measured by the working electrodes, the risk score being transmitted and produced on a display;
wherein the sensor array includes working electrodes that measure lactate and tissue oxygen and calculating the risk score includes relative weighting factors assigned to each of the analytes being measured, the relative weighting measurements being stored in the memory of the electronics module.
26. The system of claims 25 , wherein at least one of the relative weighting factors is automatically adjusted based on historical data acquired by the sensor array.
27. The system of claim 26 , wherein calculating the risk score includes rates of change of the real-time measurements.
28. The system of claim 27 , wherein calculating the risk score further includes assigning relative weighting factors to rates of change of the real-time measurements.
29. The system of claim 28 , wherein the relative weighting factors assigned to rates of change are different than the relative weighting factors assigned to each of the analytes being measured.
30. The system of claim 29 , wherein the sensor array further includes a working electrode configured to measure a third analyte in real-time.
31. The system of claim 30 , wherein calculating the risk score includes calculating a ratio of the concentrations of any two of analytes being measured in real-time.
32. The system of claim 31 , wherein calculating the risk score further includes other data not being obtained by the sensor array.
33. A method for the early detection of sepsis in a host, comprising the operations of:
inserting a sensor assembly capable of measuring a plurality of analytes in real-time, the sensor assembly being placed into subcutaneous tissue of the host via a single point of entry;
measuring a lactate level of the host;
measuring a tissue oxygen level of the host; and
determining a risk score for developing sepsis based on predetermined correlations between the plurality of analytes.
34. The method of claim 33 , further including the operation of:
measuring a glucose level of the host, wherein determining the risk scored for developing sepsis is based on predetermined correlations between at least two of the plurality of analytes.
35. The method of claim 34 , wherein the predetermined correlations between the plurality of analytes includes calculating a ratio of concentrations of at least two of the plurality of analytes.
36. The method of claim 34 , wherein the predetermined correlations between the plurality of analytes includes calculating a rate of change of concentrations of at least two of the plurality of analytes.
37. The method of claim 34 , wherein the real-time measurements are continuously taken at predetermined intervals.
38. The method of claim 37 , wherein the predetermined intervals are dynamically determined based on at least one of the real-time measurements from the sensor assembly.
39. The method of claim 37 , wherein each analyte is measured at a different predetermined interval.
40. The method of claim 34 , wherein calculating the risk score further includes other data not being obtained by the sensor array.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/100,833 US20210236065A1 (en) | 2016-05-13 | 2020-11-21 | System and method for disease risk assessment and treatment |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662336482P | 2016-05-13 | 2016-05-13 | |
US201662348806P | 2016-06-10 | 2016-06-10 | |
US201662353559P | 2016-06-23 | 2016-06-23 | |
US201662370226P | 2016-08-02 | 2016-08-02 | |
US201662383233P | 2016-09-02 | 2016-09-02 | |
US201662401481P | 2016-09-29 | 2016-09-29 | |
US201762443070P | 2017-01-06 | 2017-01-06 | |
US15/417,055 US10888281B2 (en) | 2016-05-13 | 2017-01-26 | System and method for disease risk assessment and treatment |
US17/100,833 US20210236065A1 (en) | 2016-05-13 | 2020-11-21 | System and method for disease risk assessment and treatment |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/417,055 Continuation US10888281B2 (en) | 2016-05-13 | 2017-01-26 | System and method for disease risk assessment and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210236065A1 true US20210236065A1 (en) | 2021-08-05 |
Family
ID=60266784
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/417,055 Active 2038-10-01 US10888281B2 (en) | 2016-05-13 | 2017-01-26 | System and method for disease risk assessment and treatment |
US17/100,833 Pending US20210236065A1 (en) | 2016-05-13 | 2020-11-21 | System and method for disease risk assessment and treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/417,055 Active 2038-10-01 US10888281B2 (en) | 2016-05-13 | 2017-01-26 | System and method for disease risk assessment and treatment |
Country Status (3)
Country | Link |
---|---|
US (2) | US10888281B2 (en) |
EP (1) | EP3454750A1 (en) |
WO (1) | WO2017196576A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11166799B2 (en) * | 2017-05-19 | 2021-11-09 | Maxim Integrated Products, Inc. | Physiological condition determination system |
EP3485801A1 (en) * | 2017-11-19 | 2019-05-22 | Indigo Diabetes N.V. | Implantable integrated sensor device |
US11529053B2 (en) | 2017-12-20 | 2022-12-20 | PercuSense, Inc. | System and method for disease risk assessment and treatment |
CA3100015A1 (en) * | 2018-04-17 | 2019-10-24 | Steven B. Waltman | Monitoring catabolism markers |
US20210391084A1 (en) * | 2018-10-15 | 2021-12-16 | Rhonda Fay Adams | Clinical smart watch for addressing adverse cardiac events |
WO2020086895A1 (en) * | 2018-10-24 | 2020-04-30 | Scivera LLC | Computer-implemented method for quantifying chemical hazard assessment |
US11160503B2 (en) * | 2019-04-23 | 2021-11-02 | Fresenius Medical Care Holdings, Inc. | Wearable continuous vascular access monitor |
CN110442035A (en) * | 2019-08-22 | 2019-11-12 | 梅钟可 | A kind of multichannel human body information collection analysis smart home system |
CN114845634A (en) * | 2019-12-26 | 2022-08-02 | 德克斯康公司 | Systems and methods for sepsis risk assessment |
US20210361175A1 (en) * | 2020-05-20 | 2021-11-25 | Koninklijke Philips N.V. | Sleep-based biometric to predict and track viral infection phases |
AU2021287250A1 (en) * | 2020-06-08 | 2022-12-15 | Abbott Diabetes Care Inc. | Systems, devices, and methods for improved analyte sensor accuracy and fault detection |
GB2598568A (en) * | 2020-09-01 | 2022-03-09 | Clini Hub Ltd | Patient monitoring device |
WO2022146860A1 (en) * | 2021-01-04 | 2022-07-07 | Medtronic, Inc. | Detection of infection in a patient |
US11831688B2 (en) * | 2021-06-18 | 2023-11-28 | Capital One Services, Llc | Systems and methods for network security |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050065556A1 (en) * | 2003-09-23 | 2005-03-24 | Medtronic Minimed, Inc. | Implantable multi-parameter sensing system and method |
US20090299767A1 (en) * | 2006-04-27 | 2009-12-03 | 32 Mott Street Acquisition I Llc, D/B/A/Wellstat Vaccines | Automated systems and methods for obtaining, storing, processing and utilizing immunologic information of individuals and populations for various uses |
US20100324436A1 (en) * | 2008-02-04 | 2010-12-23 | University Of Virginia Patent Foundation | System, Method and Computer Program Product for Detection of Changes in Health Status and Risk of Imminent Illness |
US20120130201A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Dyspnea |
US20160239611A1 (en) * | 2015-02-17 | 2016-08-18 | Massachusetts Institute Of Technology | System and method for sepsis care task management |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5724983A (en) | 1994-08-01 | 1998-03-10 | New England Center Hospitals, Inc. | Continuous monitoring using a predictive instrument |
WO2002015777A1 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Methods and devices for prediction of hypoglycemic events |
AUPR343401A0 (en) | 2001-02-28 | 2001-03-29 | Nguyen, Hung | Modelling and design for early warning systems using physiological responses |
US20030032871A1 (en) | 2001-07-18 | 2003-02-13 | New England Medical Center Hospitals, Inc. | Adjustable coefficients to customize predictive instruments |
US7022070B2 (en) | 2002-03-22 | 2006-04-04 | Mini-Mitter Co., Inc. | Method for continuous monitoring of patients to detect the potential onset of sepsis |
DK1677668T3 (en) | 2003-10-13 | 2010-10-25 | Novo Nordisk As | Apparatus and method for determining a physiological state |
WO2005077260A1 (en) | 2004-02-12 | 2005-08-25 | Biopeak Corporation | Non-invasive method and apparatus for determining a physiological parameter |
US7097662B2 (en) * | 2004-08-25 | 2006-08-29 | Ut-Battelle, Llc | In-vivo orthopedic implant diagnostic device for sensing load, wear, and infection |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
EP1904941A4 (en) | 2005-07-18 | 2009-10-21 | Integralis Ltd | Apparatus, method and computer readable code for forecasting the onset of potentially life-threatening disease |
CN102908130B (en) | 2005-11-29 | 2015-04-22 | 风险获利有限公司 | Device for monitoring human health |
US8016776B2 (en) | 2005-12-02 | 2011-09-13 | Medtronic, Inc. | Wearable ambulatory data recorder |
US20120095304A1 (en) | 2005-12-15 | 2012-04-19 | Cardiopulmonary Corporation | System and Method for Determining a Patient Clinical Status |
US7941199B2 (en) | 2006-05-15 | 2011-05-10 | Masimo Laboratories, Inc. | Sepsis monitor |
US10163174B2 (en) | 2006-05-30 | 2018-12-25 | The University Of North Carolina At Chapel Hill | Methods, systems, and computer program products for evaluating a patient in a pediatric intensive care unit |
WO2008089282A2 (en) * | 2007-01-16 | 2008-07-24 | Silver James H | Sensors for detecting subtances indicative of stroke, ischemia, infection or inflammation |
US8412293B2 (en) | 2007-07-16 | 2013-04-02 | Optiscan Biomedical Corporation | Systems and methods for determining physiological parameters using measured analyte values |
WO2009036369A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | System and methods for wireless body fluid monitoring |
US20090076345A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Adherent Device with Multiple Physiological Sensors |
WO2009048977A1 (en) | 2007-10-08 | 2009-04-16 | Optiscan Biomedical Corporation | Low draw volume analyte detection systems |
WO2009075796A1 (en) | 2007-12-05 | 2009-06-18 | Massachusetts Institute Of Technology | System and method for predicting septic shock |
FR2924847B1 (en) | 2007-12-06 | 2014-08-29 | Vigilio | METHOD AND EQUIPMENT FOR DETECTING CRITICAL SITUATION OF A SUBJECT |
US20090163774A1 (en) | 2007-12-20 | 2009-06-25 | Sudeesh Thatha | Managment and Diagnostic System for Patient Monitoring and Symptom Analysis |
WO2009114548A1 (en) | 2008-03-12 | 2009-09-17 | Corventis, Inc. | Heart failure decompensation prediction based on cardiac rhythm |
US20100274102A1 (en) | 2009-04-22 | 2010-10-28 | Streamline Automation, Llc | Processing Physiological Sensor Data Using a Physiological Model Combined with a Probabilistic Processor |
US9060722B2 (en) | 2009-04-22 | 2015-06-23 | Rodrigo E. Teixeira | Apparatus for processing physiological sensor data using a physiological model and method of operation therefor |
US20120209088A1 (en) | 2009-09-30 | 2012-08-16 | Healthwatch Ltd. | Continuous non-interfering health monitoring and alert system |
US8527449B2 (en) | 2009-11-05 | 2013-09-03 | Mayo Foundation For Medical Education And Research | Sepsis monitoring and control |
EP2534597B1 (en) | 2010-03-15 | 2018-10-17 | Singapore Health Services Pte Ltd | Method of predicting the survivability of a patient |
WO2011149565A1 (en) | 2010-05-28 | 2011-12-01 | Research Triangle Institute, International | Apparatus, system, and method for seizure symptom detection |
US9719842B2 (en) | 2010-07-06 | 2017-08-01 | Norman A. Paradis | Method for the discovery, validation and clinical application of multiplex biomarker algorithms based on optical, physical and/or electromagnetic patterns |
US8814792B2 (en) | 2010-07-27 | 2014-08-26 | Carefusion 303, Inc. | System and method for storing and forwarding data from a vital-signs monitor |
GB201018774D0 (en) | 2010-11-05 | 2010-12-22 | Learning Clinic The Ltd | A system and method for monitoring the health of a hospital patient |
WO2012109447A1 (en) | 2011-02-09 | 2012-08-16 | The Charles Stark Draper Laboratory, Inc. | Wireless, implantable electro-encephalography system |
US20130338543A1 (en) | 2011-03-01 | 2013-12-19 | Koninklijke Philips N.V. | Patient deterioration detection |
US10925580B2 (en) | 2011-08-29 | 2021-02-23 | Alexander Francis Castellanos 2002 Trust | Mobile vascular health evaluation devices using doppler ultrasound and correlation of parameters to output recommendations to a wrist-mounted display |
US10327714B2 (en) | 2012-03-29 | 2019-06-25 | Senseonics, Incorporated | Analyte concentration alert function for analyte sensor system |
CN103778312B (en) | 2012-10-24 | 2017-05-10 | 中兴通讯股份有限公司 | Remote home health care system |
US20140236025A1 (en) | 2013-02-15 | 2014-08-21 | Michael L. Sheldon | Personal Health Monitoring System |
US10149617B2 (en) | 2013-03-15 | 2018-12-11 | i4c Innovations Inc. | Multiple sensors for monitoring health and wellness of an animal |
US20140350352A1 (en) | 2013-05-23 | 2014-11-27 | Children's Medical Center Corporation | System and method of assessing stability of patients |
US20150025329A1 (en) | 2013-07-18 | 2015-01-22 | Parkland Center For Clinical Innovation | Patient care surveillance system and method |
US20150148617A1 (en) | 2013-11-27 | 2015-05-28 | General Electric Company | Method and system for selecting alarm reduction algorithm |
US10490049B2 (en) | 2013-12-10 | 2019-11-26 | General Electric Company | Systems and methods for identifying patient distress |
US9968288B2 (en) | 2014-03-26 | 2018-05-15 | Eco-Fusion | Systems and methods for predicting seizures |
US20160143596A1 (en) | 2014-04-16 | 2016-05-26 | Xerox Corporation | Assessing patient risk of an acute hypotensive episode with vital measurements |
US20150342538A1 (en) | 2014-06-03 | 2015-12-03 | Welch Allyn, Inc. | Custom early warning scoring for medical device |
GB2532919B (en) | 2014-10-24 | 2019-05-15 | Cambridge temperature concepts ltd | Monitoring physiology |
US10653369B2 (en) | 2014-12-23 | 2020-05-19 | Intel Corporation | Device for health monitoring and response |
GB2533774A (en) | 2014-12-23 | 2016-07-06 | Fertility Focus Ltd | Data processing based on multiple inputs |
US20160220127A1 (en) | 2015-02-03 | 2016-08-04 | Covidien Lp | Wellness or illness assessment system, method, and computer program product |
-
2017
- 2017-01-26 US US15/417,055 patent/US10888281B2/en active Active
- 2017-05-01 EP EP17733193.1A patent/EP3454750A1/en active Pending
- 2017-05-01 WO PCT/US2017/030438 patent/WO2017196576A1/en unknown
-
2020
- 2020-11-21 US US17/100,833 patent/US20210236065A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050065556A1 (en) * | 2003-09-23 | 2005-03-24 | Medtronic Minimed, Inc. | Implantable multi-parameter sensing system and method |
US20090299767A1 (en) * | 2006-04-27 | 2009-12-03 | 32 Mott Street Acquisition I Llc, D/B/A/Wellstat Vaccines | Automated systems and methods for obtaining, storing, processing and utilizing immunologic information of individuals and populations for various uses |
US20100324436A1 (en) * | 2008-02-04 | 2010-12-23 | University Of Virginia Patent Foundation | System, Method and Computer Program Product for Detection of Changes in Health Status and Risk of Imminent Illness |
US20120130201A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Dyspnea |
US20160239611A1 (en) * | 2015-02-17 | 2016-08-18 | Massachusetts Institute Of Technology | System and method for sepsis care task management |
Also Published As
Publication number | Publication date |
---|---|
US20170325749A1 (en) | 2017-11-16 |
US10888281B2 (en) | 2021-01-12 |
EP3454750A1 (en) | 2019-03-20 |
WO2017196576A1 (en) | 2017-11-16 |
WO2017196576A4 (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210236065A1 (en) | System and method for disease risk assessment and treatment | |
JP7071338B2 (en) | Systems and methods for managing and analyzing data generated by embedded devices | |
US20230404412A1 (en) | Rapid detection of bleeding before, during, and after fluid resuscitation | |
US20180301220A1 (en) | Wearable Sensor Packages and Health Score Analytics for Athletic Performance and Training | |
US10206631B2 (en) | Automotive key device, steering wheel docking station, and system including the automotive key device and the steering wheel docking station | |
JP2020072774A (en) | Remote biometric monitoring and communication system | |
US20230075014A1 (en) | System and method for disease risk assessment and treatment | |
JP2017534421A (en) | Rapid detection of bleeding before, during, and after resuscitation by infusion | |
EP3468457A1 (en) | Rapid detection of bleeding following injury | |
US11406269B2 (en) | Rapid detection of bleeding following injury | |
US20190021659A1 (en) | Wireless Medical Evaluation Device | |
CA2929819A1 (en) | Noninvasive predictive and/or estimative blood pressure monitoring | |
CA2930593A1 (en) | Noninvasive hydration monitoring | |
Chowdary et al. | An efficient wireless health monitoring system | |
US11284816B2 (en) | Multi-analyte continuous glucose monitoring | |
US20240075271A1 (en) | Wireless Communication and Power Conservation for Implantable Monitors | |
US20220211332A1 (en) | Medical device system for monitoring patient health | |
WO2020157557A1 (en) | A monitoring and prediction system of diuresis for the calculation of kidney failure risk, and the method thereof | |
US20240057905A1 (en) | Multi-analyte continuous glucose monitoring | |
Chirchi et al. | Context Monitoring of Patients using Wireless Network | |
US20210196206A1 (en) | Systems and methods for sepsis risk evaluation | |
Manoharan et al. | An Intelligent Non-Invasive Sweat-Based Glucose Monitoring System for Managing Diabetes Mellitus | |
Anand et al. | Remote Patient Monitoring: An Overview of Technologies, Applications, and Challenges | |
TWM448030U (en) | Wireless vital signal management system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |